"commentId","patientdr","commentType","drugType","comment"
"99","15","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"100","15","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"101","15","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"102","15","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"103","15","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"104","15","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"105","15","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"106","15","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"107","15","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"108","15","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"109","15","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"110","15","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"111","15","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"112","15","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"113","15","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"114","16","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"115","16","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"116","16","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"117","16","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"118","16","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"119","16","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"120","16","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"121","16","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"122","16","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"123","16","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"124","16","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"125","16","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"126","17","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"127","17","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"128","18","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"129","18","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"130","18","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"131","19","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"132","19","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"133","19","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"134","19","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"135","19","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"136","19","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"137","19","rtComments","NNRTI","V106A is a non-polymorphic mutation that causes high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR."
"138","19","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"139","19","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"140","20","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"141","20","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"142","20","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"143","20","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"144","20","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"145","20","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"146","20","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"147","20","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"148","20","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"149","20","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"150","20","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"151","21","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"152","21","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"153","21","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"154","21","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"155","21","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"156","22","rtComments","Accessory","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV. I47M is a highly unusual mutation at this position."
"157","22","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"158","23","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"159","23","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"160","23","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"161","23","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"162","23","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"163","23","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"164","24","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"165","24","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"166","24","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"167","24","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"168","25","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"169","25","rtComments","Accessory","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to the remaining PIs. I50M is a highly unusual mutation at this position."
"170","25","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"171","25","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"172","25","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"173","25","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"174","26","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"175","26","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"176","26","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"177","27","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"178","27","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"179","27","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"180","27","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"181","27","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"182","27","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"183","27","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"184","27","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"185","27","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"186","28","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"187","28","rtComments","Major","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score."
"188","28","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"189","28","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"190","28","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"191","28","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"192","28","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"193","28","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"194","28","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"195","28","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"196","28","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"197","28","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"198","28","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"199","28","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"200","28","rtComments","NNRTI","Y188H is a non-polymorphic mutation selected in patients receiving NVP and EFV. It causes about 5 to 10-fold reduced susceptibility to NVP and EFV. It appears to cause little if any reduction in susceptibility to RPV, ETR, or DOR."
"201","29","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"202","29","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"203","30","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"204","31","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"205","31","rtComments","Accessory","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score. V32A is a highly unusual mutation at this position."
"206","31","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"207","31","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"208","31","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"209","32","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"210","32","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"211","32","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"212","32","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"213","32","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"214","32","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"215","32","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"216","32","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"217","32","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"218","33","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"219","33","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"220","33","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"221","33","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"222","33","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"223","33","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"224","33","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"225","33","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"226","33","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"227","33","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"228","33","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"229","33","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"230","34","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"231","34","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"232","35","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"233","35","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"234","35","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"235","35","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"236","35","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"237","35","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"238","35","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"239","35","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"240","35","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"241","35","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"242","35","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"243","35","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"244","35","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"245","35","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"246","36","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"247","36","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"248","36","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"249","36","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"250","36","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"251","36","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"252","36","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"253","37","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"254","37","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"255","37","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"256","37","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"257","37","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"258","37","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"259","37","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"260","37","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"261","37","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"262","37","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"263","37","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"264","37","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"265","37","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"266","37","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"267","37","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"268","38","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"269","38","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"270","38","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"271","38","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"272","39","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"273","40","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"274","41","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"275","41","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"276","41","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"277","41","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"278","42","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"279","42","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"280","42","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"281","42","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"282","42","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"283","42","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"284","42","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"285","42","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"286","42","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"308","48","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"309","48","rtComments","2","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"310","48","rtComments","3","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV"
"311","48","rtComments","4","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"312","48","rtComments","5","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"313","48","rtComments","6","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"314","48","rtComments","7","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"315","51","prComments","1","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"316","51","rtComments","1","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility s"
"317","51","rtComments","2","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"318","51","rtComments","3","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"319","51","rtComments","4","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"320","51","rtComments","5","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215"
"321","51","rtComments","6","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"322","51","rtComments","7","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"323","51","rtComments","8","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"324","53","rtComments","1","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce th"
"325","53","rtComments","2","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"326","53","rtComments","3","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"327","53","rtComments","4","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be "
"328","53","rtComments","5","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV"
"329","53","rtComments","6","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by &gt;50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by onl"
"330","53","rtComments","7","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"331","53","rtComments","8","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"332","53","rtComments","9","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"333","53","rtComments","10","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"334","54","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"335","54","rtComments","2","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibi"
"336","54","rtComments","3","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"337","54","rtComments","4","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"338","54","rtComments","5","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"339","56","rtComments","1","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"340","56","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"341","57","prComments","1","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"342","58","prComments","1","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"343","58","prComments","2","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that h"
"344","58","prComments","3","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"345","58","prComments","4","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"346","58","prComments","5","K20R is a highly polymorphic PI-selected accessory mutation."
"347","58","prComments","6","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"348","58","prComments","7","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"349","58","rtComments","1","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to "
"350","58","rtComments","2","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"351","58","rtComments","3","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"352","58","rtComments","4","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"353","58","rtComments","5","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"354","58","rtComments","6","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"355","58","rtComments","7","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"356","58","rtComments","8","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"357","59","rtComments","1","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"358","60","rtComments","1","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"359","61","prComments","1","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"360","61","rtComments","1","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV"
"361","61","rtComments","2","Y318F is an uncommon mutation that causes intermediate NVP resistance and potentially low-level EFV resistance. It has been selected in vivo by DOR and in combination with other mutations it has been associated with high-level reductions in DOR susce"
"362","61","rtComments","3","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"363","62","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"364","63","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"365","63","rtComments","2","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"366","63","rtComments","3","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"367","64","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"368","64","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"369","64","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"370","64","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"371","64","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"372","65","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"373","65","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"374","67","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"375","67","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"376","67","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"377","67","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"378","68","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"379","68","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"380","68","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"381","69","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"382","70","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"383","71","rtComments","Major","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. It is included in the Tibotec DRV genotypic susceptibility score."
"384","71","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"385","71","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"386","72","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"387","72","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"388","72","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"389","72","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"390","72","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied."
"391","72","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"392","72","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"393","72","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"394","72","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"395","72","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"396","72","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"397","72","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"398","72","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"399","72","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"400","72","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"401","73","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46K is a highly unusual mutation at this position."
"402","73","rtComments","Accessory","G48V is a non-polymorphic mutation selected by SQV and, less often, by IDV and LPV. It confers high-level resistance to SQV, intermediate-level resistance to ATV, and low-level resistance to NFV, IDV and LPV. G48M is a non-polymorphic mutation selected in viruses with multiple PI-resistance mutations. Its effects appear to be similar to those of G48V. G48A/S/T/Q are rare non-polymorphic mutations selected in viruses with multiple PI-resistance mutations. G48R is a highly unusual mutation at this position."
"403","73","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"404","73","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"405","73","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"406","73","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"407","74","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"408","74","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"409","75","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"410","75","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"411","75","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"412","75","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"413","76","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"414","76","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"415","76","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"416","76","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"417","76","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"418","76","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"419","77","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"420","77","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"421","77","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"422","77","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"423","77","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"424","78","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"425","78","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"426","78","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"427","78","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"428","78","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"429","78","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"430","78","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"431","78","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"432","79","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"433","79","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"434","79","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"435","79","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"436","79","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"437","79","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"438","79","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"439","79","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"440","79","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"441","79","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"442","79","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"443","79","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"444","80","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"445","80","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"446","81","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"447","82","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"448","82","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"449","82","rtComments","Other","I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied."
"450","82","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"451","82","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"452","82","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"453","82","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"454","82","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"455","82","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"456","82","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"457","83","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"458","83","rtComments","Accessory","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score. V32A is a highly unusual mutation at this position."
"459","83","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"460","83","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied."
"461","83","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"462","83","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"463","83","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"464","83","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"465","83","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"466","83","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"467","83","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"468","83","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"469","83","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"470","83","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"471","83","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"472","83","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"473","83","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"474","83","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"475","84","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"476","84","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"477","84","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"478","84","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"479","84","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"480","84","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"481","84","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"482","84","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"483","84","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"484","84","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"485","85","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"486","85","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"487","85","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"488","85","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"489","85","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"490","85","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"491","86","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"492","86","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"493","87","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"494","87","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"495","88","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"496","88","rtComments","Major","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. It is included in the Tibotec DRV genotypic susceptibility score."
"497","88","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"498","88","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"499","88","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"500","88","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"501","88","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"502","88","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"503","89","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"504","89","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"505","89","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"506","89","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"507","90","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"508","90","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"509","90","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"510","90","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"511","90","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"512","91","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"513","91","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"514","91","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"515","91","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"516","91","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"517","91","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"518","91","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"519","91","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"520","91","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"521","91","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"522","92","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"523","92","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"524","92","rtComments","Other","M230L causes intermediate to high-level resistance to each of the NNRTIs. M230I is an extremely rare mutation selected in vitro by RPV. M230R is a highly unusual mutation at this position."
"525","93","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"526","93","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"527","95","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"528","95","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"529","95","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"530","95","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"531","95","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"532","95","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"533","96","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"534","96","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"535","96","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"536","96","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"537","97","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"538","97","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"539","97","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"540","97","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"541","97","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"542","97","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179N is an unusual mutation at this position."
"543","98","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"544","98","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"545","99","rtComments","Major","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score."
"546","99","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"547","99","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"548","99","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"549","99","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"550","99","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"551","99","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"552","99","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"553","99","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"554","99","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"555","99","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"556","99","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"557","99","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"558","100","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"559","100","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"560","101","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"561","101","rtComments","Other","K101E/H/P are NNRTI-resistance mutations. K101G is a highly unusual mutation at this position."
"562","101","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"563","101","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"564","101","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"565","101","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"566","101","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"567","101","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"568","101","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"569","101","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"570","101","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"571","102","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"572","102","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"573","102","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"574","103","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"575","103","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"576","103","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"577","103","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"578","103","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10H is a highly unusual mutation at this position."
"579","103","rtComments","Other","L10R/Y are rare, non-polymorphic PI-selected mutations. Their effects on PI susceptibility have not been well studied."
"580","103","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"581","103","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"582","103","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"583","103","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"584","103","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"585","103","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"586","103","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"587","103","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"588","103","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"589","103","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"590","103","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"591","103","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"592","103","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"593","104","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"594","104","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"595","104","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"596","104","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"597","104","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"598","104","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"599","105","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"600","105","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"601","105","rtComments","Major","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score."
"602","105","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"603","105","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"604","105","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"605","105","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"606","105","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"607","105","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"608","105","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"609","105","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"610","105","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"611","105","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"612","105","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"613","105","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"614","105","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"615","105","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"616","105","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"617","106","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"618","106","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"619","106","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"620","106","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"621","107","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"622","107","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"623","107","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied."
"624","107","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"625","107","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"626","107","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"627","107","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"628","107","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"629","107","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"630","107","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"631","107","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"632","107","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"633","107","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"634","107","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"635","107","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"636","108","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"637","108","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"638","108","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"639","108","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"640","109","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"641","109","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"642","109","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"643","109","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"644","109","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"645","109","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"646","109","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"647","109","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"648","109","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"649","109","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"650","109","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"651","109","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"652","109","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"653","109","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"654","109","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"655","109","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"656","109","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"657","109","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"658","111","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"659","111","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"660","111","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"661","111","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"662","111","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"663","112","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"664","112","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"665","112","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"666","112","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"667","112","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"668","113","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"669","113","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"670","113","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"671","113","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"672","114","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"673","114","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"674","115","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"675","115","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"676","115","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"677","116","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"678","116","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"679","116","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"680","117","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"681","117","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"682","117","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"683","117","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"684","118","rtComments","Major","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score."
"685","118","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"686","118","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"687","118","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"688","118","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"689","118","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"690","118","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"691","118","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"692","118","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"693","118","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"694","118","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"695","118","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"696","118","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"697","118","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"698","118","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"699","118","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"700","118","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"701","118","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"702","119","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"703","119","rtComments","Major","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score."
"704","119","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"705","119","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"706","119","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"707","119","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"708","119","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"709","119","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"710","119","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"711","119","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"712","119","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"713","119","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"714","119","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"715","119","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"716","119","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"717","120","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"718","120","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"719","120","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"720","120","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"721","120","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"722","120","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"723","120","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"724","120","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"725","120","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"726","120","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"727","120","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"728","121","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"729","121","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"730","121","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"731","121","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"732","121","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"733","121","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"734","121","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"735","122","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"736","122","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"737","122","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"738","122","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"739","122","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"740","122","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"741","122","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"742","122","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"743","122","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"744","122","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"745","122","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"746","122","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"747","122","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"748","122","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"749","122","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"750","123","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"751","123","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"752","123","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"753","123","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"754","123","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"755","123","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"756","123","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"757","123","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"758","123","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"759","123","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"760","123","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"761","123","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"762","123","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"763","123","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"764","123","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"765","123","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"766","124","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"767","124","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"768","124","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"769","124","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"770","124","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"771","124","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"772","124","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"773","125","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"774","125","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"775","125","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"776","125","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"777","125","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"778","126","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"779","126","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"780","126","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"781","126","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"782","126","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"783","127","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"784","128","rtComments","Major","V82F is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs."
"785","128","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"786","128","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"787","128","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"788","128","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"789","128","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"790","128","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"791","128","rtComments","Other","E138K is a non-polymorphic RPV-resistance mutation. E138A/Q/G/R are less well studied mutations associated with reduced ETR and RPV susceptibility. E138T is an unusual mutation at this position."
"792","128","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"793","128","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"794","128","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"795","128","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"796","128","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"797","128","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"798","128","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"799","128","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"800","128","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"801","128","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"802","128","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"803","128","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"804","128","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"805","128","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"806","128","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"807","129","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"808","129","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"809","130","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"810","130","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"811","130","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"812","131","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"813","131","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"814","131","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"815","131","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"816","131","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"817","131","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"818","131","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"819","131","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"820","131","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"821","131","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"822","131","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"823","131","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"824","131","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"825","131","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"826","133","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"827","133","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"828","134","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"829","135","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"830","135","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"831","135","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"832","135","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"833","136","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"834","137","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"835","137","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"836","137","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"837","137","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"838","137","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"839","137","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"840","138","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"841","138","rtComments","NNRTI","K103E/Q are rare mutations that have not been associated with reduced NNRTI susceptibility."
"842","140","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"843","140","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"844","140","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"845","140","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"846","140","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"847","140","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"848","140","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"849","140","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"850","140","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"851","140","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"852","140","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"853","140","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"854","140","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"855","140","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"856","140","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"857","140","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"858","141","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"859","141","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"860","141","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"861","141","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"862","141","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"863","141","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"864","141","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"865","141","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"866","142","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"867","142","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"868","142","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"869","142","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"870","142","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"871","142","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"872","142","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"873","142","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"874","142","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"875","142","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"876","142","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"877","142","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"878","142","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"879","142","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219D is an unusual mutation at this position."
"880","143","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"881","143","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"882","143","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"883","144","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"884","145","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"885","145","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"886","146","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"887","146","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"888","146","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"889","146","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"890","146","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"891","146","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"892","146","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"893","146","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"894","146","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"895","147","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"896","147","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"897","147","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"898","147","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"899","148","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"900","148","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"901","149","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"902","149","rtComments","Major","In most subtypes, V82M is a 2-base-pair mutation that develops in viruses with multiple other PI-resistance mutations. In subtype G, V82M is a 1-base-pair mutation. V82M reduces susceptibility to IDV, LPV and possibly other PIs."
"903","149","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"904","149","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"905","149","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"906","149","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"907","149","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"908","149","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"909","149","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"910","149","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"911","149","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"912","149","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"913","149","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"914","150","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"915","150","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"916","151","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"917","151","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"918","151","rtComments","NNRTI","F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
"919","151","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"920","151","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"921","152","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"922","152","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"923","153","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"924","153","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"925","154","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"926","154","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"927","154","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"928","155","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"929","155","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"930","155","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"931","155","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"932","155","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"933","155","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"934","155","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"935","155","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"936","155","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"937","155","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"938","155","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"939","155","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"940","155","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"941","155","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"942","155","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"943","155","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"944","155","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"945","155","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"946","155","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"947","155","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"948","156","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"949","156","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"950","156","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"951","156","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"952","156","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"953","156","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"954","157","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"955","158","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"956","158","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"957","158","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"958","159","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"959","160","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"960","161","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"961","161","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"962","161","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"963","161","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"964","161","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"965","161","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"966","161","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"967","161","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"968","161","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"969","161","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"970","161","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"971","161","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"972","161","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"973","161","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"974","161","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"975","161","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"976","161","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"977","161","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"978","161","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"979","162","rtComments","NRTI","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"980","162","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"981","162","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"982","162","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"983","162","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"984","162","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"985","163","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"986","163","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"987","163","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"988","163","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"989","163","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"990","163","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"991","163","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"992","165","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"993","165","rtComments","NNRTI","V106A is a non-polymorphic mutation that causes high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR."
"994","165","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"995","166","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"996","166","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"997","166","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"998","167","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"999","167","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1000","167","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1001","167","rtComments","Accessory","T74P is a non-polymorphic PI-selected accessory mutation that occurs primarily in viruses from patients who have received multiple PIs. It is associated with reduced susceptibility to each of the PIs. It is included in the Boehringer-Ingelheim TPV and Tibotec DRV genotypic susceptibility scores."
"1002","167","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1003","167","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1004","167","rtComments","Other","Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M. Q151K is a highly unusual mutation at this position."
"1005","167","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1006","167","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1007","167","rtComments","NRTI","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"1008","167","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"1009","167","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"1010","167","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1011","167","rtComments","NRTI","F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
"1012","167","rtComments","NRTI","Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M."
"1013","167","rtComments","NRTI","Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
"1014","167","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1015","167","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"1016","167","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1017","167","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1018","167","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1019","168","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1020","168","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1021","168","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1022","168","rtComments","Accessory","T74P is a non-polymorphic PI-selected accessory mutation that occurs primarily in viruses from patients who have received multiple PIs. It is associated with reduced susceptibility to each of the PIs. It is included in the Boehringer-Ingelheim TPV and Tibotec DRV genotypic susceptibility scores."
"1023","168","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1024","168","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1025","168","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"1026","168","rtComments","Other","Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M. Q151K is a highly unusual mutation at this position."
"1027","168","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1028","168","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1029","168","rtComments","NRTI","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"1030","168","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"1031","168","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"1032","168","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1033","168","rtComments","NRTI","F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
"1034","168","rtComments","NRTI","Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC. Q151L is an extremely rare transitional mutation that may precede the emergence of the Q151M."
"1035","168","rtComments","NRTI","Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
"1036","168","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1037","168","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"1038","168","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1039","168","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1040","168","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1041","169","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"1042","169","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1043","169","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1044","169","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1045","169","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1046","171","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1047","171","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1048","172","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1049","172","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1050","172","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1051","172","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1052","172","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"1053","172","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"1054","173","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1055","173","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"1056","174","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1057","174","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1058","174","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1059","174","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1060","174","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1061","175","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1062","175","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"1063","175","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1064","175","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1065","175","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"1066","175","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1067","175","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1068","175","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1069","175","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1070","175","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"1071","175","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1072","175","rtComments","Other","M230L causes intermediate to high-level resistance to each of the NNRTIs. M230I is an extremely rare mutation selected in vitro by RPV. M230R is a highly unusual mutation at this position."
"1073","175","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"1074","175","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1075","175","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1076","175","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1077","175","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"1078","175","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1079","175","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"1080","175","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"1081","176","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1082","176","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1083","177","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1084","177","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1085","177","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1086","177","rtComments","NNRTI","V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
"1087","177","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1088","177","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1089","178","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"1090","178","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1091","178","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1092","178","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1093","179","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1094","179","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1095","179","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1096","179","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"1097","179","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1098","179","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1099","179","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1100","179","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1101","179","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1102","179","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1103","179","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1104","179","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1105","179","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1106","179","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1107","179","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1108","179","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1109","179","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1110","180","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1111","180","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"1112","180","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"1113","180","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1114","180","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1115","180","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"1116","180","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1117","180","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"1118","180","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1119","180","rtComments","NNRTI","V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"1120","180","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"1121","180","rtComments","NNRTI","F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
"1122","181","rtComments","Accessory","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV. I47R is a highly unusual mutation at this position."
"1123","181","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1124","181","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1125","181","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1126","181","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1127","181","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1128","181","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1129","181","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1130","181","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1131","182","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1132","183","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1133","183","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1134","183","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1135","183","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"1136","183","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1137","183","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1138","183","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"1139","183","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1140","183","rtComments","NNRTI","F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
"1141","184","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1142","184","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1143","184","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1144","184","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1145","184","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1146","184","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1147","184","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1148","184","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1149","184","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1150","184","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1151","184","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1152","184","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1153","185","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1154","186","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1155","186","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1156","186","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1157","186","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1158","187","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1159","187","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1160","187","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"1161","187","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1162","187","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1163","187","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1164","187","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1165","187","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1166","188","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1167","188","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1168","188","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"1169","188","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1170","188","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"1171","188","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1172","189","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1173","189","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1174","190","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1175","190","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1176","190","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1177","190","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1178","190","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1179","191","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1180","191","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1181","191","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1182","191","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1183","192","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1184","192","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1185","192","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1186","192","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1187","192","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1188","192","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1189","192","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1190","192","rtComments","NNRTI","Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
"1191","194","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"1192","194","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1193","194","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1194","194","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1195","195","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1196","195","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1197","195","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1198","195","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1199","195","rtComments","NNRTI","V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
"1200","195","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"1201","195","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1202","196","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"1203","196","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1204","196","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1205","197","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1206","197","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1207","197","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1208","197","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"1209","197","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1210","198","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1211","198","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1212","198","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1213","199","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1214","199","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1215","199","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1216","199","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1217","199","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1218","199","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1219","199","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1220","199","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1221","200","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1222","200","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"1223","200","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1224","200","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1225","200","rtComments","NNRTI","Y181F/S/G are rare non-polymorphic NNRTI-associated mutations that are usually present as part of an electrophoretic mixture. They are likely to represent transitional mutations between Y and I or V."
"1226","202","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1227","202","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"1228","203","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1229","204","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1230","204","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1231","204","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1232","205","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"1233","205","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1234","205","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"1235","205","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1236","205","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1237","205","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1238","205","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"1239","205","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1240","205","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1241","205","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1242","205","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"1243","205","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1244","205","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1245","205","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1246","205","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1247","205","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1248","205","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1249","205","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1250","205","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1251","205","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1252","205","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1253","206","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1254","206","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1255","206","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1256","207","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1257","208","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1258","208","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1259","208","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"1260","209","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1261","209","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1262","209","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"1263","209","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1264","209","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1265","209","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1266","209","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1267","209","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1268","209","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"1269","209","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1270","209","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"1271","209","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1272","209","rtComments","NRTI","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"1273","209","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1274","209","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1275","209","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"1276","209","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1277","209","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1278","209","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1279","209","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"1280","209","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1281","209","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1282","209","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1283","210","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1284","210","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1285","210","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1286","211","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1287","211","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1288","211","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1289","211","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1290","211","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1291","211","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1292","211","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1293","211","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1294","212","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1295","212","rtComments","Other","K238T reduces NVP and EFV susceptibility by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238S is a highly unusual mutation at this position."
"1296","213","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1297","213","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1298","213","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"1299","213","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1300","214","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1301","214","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1302","214","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1303","214","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1304","214","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1305","215","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1306","215","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1307","215","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1308","215","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1309","215","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1310","216","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"1311","216","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"1312","216","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"1313","216","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1314","216","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"1315","216","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1316","216","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1317","216","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1318","216","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1319","216","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1320","216","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"1321","216","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1322","217","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1323","218","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1324","218","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1325","218","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1326","218","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"1327","218","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1328","218","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1329","218","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"1330","218","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1331","218","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"1332","218","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1333","218","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1334","218","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1335","218","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1336","218","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1337","218","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1338","218","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1339","218","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1340","219","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1341","219","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1342","219","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1343","219","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"1344","219","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1345","219","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1346","219","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1347","219","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1348","219","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1349","219","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1350","219","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1351","219","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"1352","220","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1353","220","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1354","220","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1355","220","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1356","220","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1357","220","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1358","220","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1359","221","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"1360","221","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1361","221","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1362","221","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1363","221","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"1364","221","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1365","222","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1366","223","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1367","223","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1368","224","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1369","224","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1370","224","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1371","224","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1372","225","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"1373","225","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1374","226","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1375","226","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"1376","226","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"1377","226","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1378","226","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1379","226","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1380","226","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1381","226","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1382","226","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1383","227","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1384","227","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1385","228","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1386","228","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1387","228","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1388","228","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1389","228","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1390","228","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1391","228","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1392","228","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1393","228","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1394","228","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1395","228","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1396","229","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1397","229","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1398","229","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1399","230","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1400","231","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1401","231","rtComments","Major","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. It is included in the Tibotec DRV genotypic susceptibility score."
"1402","231","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1403","231","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"1404","231","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1405","231","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1406","231","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1407","231","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1408","231","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1409","231","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1410","231","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1411","231","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1412","231","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1413","231","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1414","231","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1415","231","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1416","231","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1417","231","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1418","231","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"1419","231","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1420","232","rtComments","Major","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. It is included in the Tibotec DRV genotypic susceptibility score."
"1421","232","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1422","233","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1423","233","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1424","233","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1425","233","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1426","233","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1427","233","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1428","233","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1429","234","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1430","234","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1431","234","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1432","234","rtComments","NNRTI","G190E is a non-polymorphic mutation that causes intermediate to high-level resistance to each of the NNRTIs. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
"1433","234","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1434","235","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1435","235","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1436","236","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"1437","236","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1438","236","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1439","237","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1440","238","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1441","238","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1442","238","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1443","238","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1444","238","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"1445","239","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1446","239","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1447","239","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1448","239","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1449","239","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1450","240","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1451","240","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1452","240","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1453","240","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1454","241","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"1455","241","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1456","242","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1457","242","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1458","242","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1459","243","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1460","243","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1461","243","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1462","243","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"1463","243","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1464","243","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1465","243","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1466","243","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1467","243","rtComments","NNRTI","L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been well characterized."
"1468","244","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1469","244","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1470","244","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1471","245","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1472","245","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1473","245","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1474","245","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1475","245","rtComments","Other","M230L causes intermediate to high-level resistance to each of the NNRTIs. M230I is an extremely rare mutation selected in vitro by RPV. M230K is a highly unusual mutation at this position."
"1476","246","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"1477","247","prComments","1","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1478","247","rtComments","1","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1479","247","rtComments","2","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1480","247","rtComments","3","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1481","247","rtComments","4","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215"
"1482","247","rtComments","5","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1483","247","rtComments","6","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1484","249","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1485","249","rtComments","2","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibi"
"1486","249","rtComments","3","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"1487","249","rtComments","4","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1488","250","rtComments","1","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1489","250","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1490","252","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1491","252","rtComments","2","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be "
"1492","252","rtComments","3","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"1493","252","rtComments","4","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1494","253","rtComments","1","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce th"
"1495","253","rtComments","2","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility s"
"1496","253","rtComments","3","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1497","253","rtComments","4","T215Y/F cause intermediate/high-level resistance to AZT and d4T and low-level resistance to ABC, ddI and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these rev"
"1498","254","rtComments","1","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-po"
"1499","254","rtComments","2","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1500","254","rtComments","3","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1501","254","rtComments","4","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215"
"1502","255","prComments","1","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1503","255","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1504","255","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1505","256","rtComments","1","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2"
"1506","256","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1507","257","prComments","1","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1508","257","prComments","2","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1509","257","prComments","3","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1510","257","prComments","4","V82C is an uncommon non-polymorphic mutation that occurs primarily in viruses with multiple other PI-resistance mutations. Its effects on PI susceptibility have not been well studied."
"1511","258","rtComments","1","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1512","258","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1513","260","rtComments","1","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1514","262","prComments","1","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1515","262","prComments","2","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1516","262","prComments","3","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"1517","263","rtComments","1","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibi"
"1518","263","rtComments","2","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"1519","263","rtComments","3","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1520","263","rtComments","4","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"1521","264","rtComments","1","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1522","264","rtComments","2","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1523","264","rtComments","3","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"1524","265","prComments","1","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility sc"
"1525","265","prComments","2","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1526","265","prComments","3","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"1527","265","prComments","4","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1528","267","prComments","1","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1529","267","prComments","2","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"1530","267","prComments","3","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"1531","270","rtComments","1","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"1532","270","rtComments","2","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"1533","270","rtComments","3","K70R causes intermediate resistance to AZT and possibly low-level resistance to d4T and TDF. K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E increases susceptibility to AZT. K70A is an unusual mutation at this positi"
"1534","271","rtComments","1","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to "
"1535","271","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1536","272","prComments","1","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1537","272","prComments","2","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1538","272","prComments","3","K20R is a highly polymorphic PI-selected accessory mutation."
"1539","272","prComments","4","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1540","273","rtComments","1","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1541","273","rtComments","2","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1542","273","rtComments","3","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"1543","274","rtComments","1","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2"
"1544","274","rtComments","2","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"1545","274","rtComments","3","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"1546","276","prComments","1","L10F/I/V/R/Y are PI-selected accessory mutations. L10M is a highly unusual mutation at this position."
"1547","278","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1548","278","rtComments","2","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1549","278","rtComments","3","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1550","278","rtComments","4","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1551","279","rtComments","1","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1552","280","rtComments","1","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be "
"1553","280","rtComments","2","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1554","280","rtComments","3","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215"
"1555","281","rtComments","1","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"1556","281","rtComments","2","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1557","281","rtComments","3","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179S is an unusual mutation at this position."
"1558","282","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1559","282","rtComments","2","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1560","282","rtComments","3","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1561","285","rtComments","1","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce th"
"1562","285","rtComments","2","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1563","285","rtComments","3","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1564","286","prComments","1","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1565","286","prComments","2","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"1566","286","rtComments","1","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1567","287","prComments","1","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1568","287","prComments","2","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1569","287","rtComments","1","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1570","288","prComments","1","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1571","290","rtComments","1","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1572","290","rtComments","2","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1573","291","rtComments","1","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1574","291","rtComments","2","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215"
"1575","291","rtComments","3","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"1576","292","rtComments","1","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1577","292","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1578","293","rtComments","1","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1579","294","prComments","1","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1580","294","prComments","2","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1581","294","prComments","3","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1582","294","prComments","4","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1583","295","rtComments","1","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are as"
"1584","297","rtComments","1","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2"
"1585","297","rtComments","2","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1586","298","prComments","1","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1587","298","prComments","2","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1588","298","prComments","3","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1589","298","prComments","4","K20R is a highly polymorphic PI-selected accessory mutation."
"1590","299","prComments","1","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. It is included in the Tibotec DRV genotypic susceptibility score."
"1591","299","prComments","2","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1592","299","prComments","3","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1593","299","prComments","4","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1594","301","rtComments","1","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1595","302","prComments","1","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susce"
"1596","302","prComments","2","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1597","302","prComments","3","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score. V32A is a highly unusual mutation at this position."
"1598","302","prComments","4","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1599","303","prComments","1","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1600","303","prComments","2","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"1601","303","prComments","3","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1602","303","prComments","4","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1603","304","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1604","304","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1605","304","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1606","304","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1607","304","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1608","304","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1609","304","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1610","304","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1611","304","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1612","304","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"1613","305","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1614","305","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1615","306","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1616","306","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1617","306","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1618","306","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1619","306","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1620","307","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1621","307","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"1622","307","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"1623","307","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1624","307","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"1625","308","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1626","308","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"1627","308","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"1628","309","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"1629","309","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1630","309","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"1631","309","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1632","309","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"1633","309","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1634","309","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1635","309","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"1636","310","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1637","310","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1638","310","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1639","310","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1640","310","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1641","310","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1642","310","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"1643","310","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1644","311","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"1645","311","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"1646","311","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1647","311","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1648","311","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1649","311","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1650","311","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1651","311","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1652","311","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"1653","311","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1654","311","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219D is an unusual mutation at this position."
"1655","311","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1656","311","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1657","311","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1658","311","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1659","311","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1660","311","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1661","311","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"1662","311","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1663","312","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1664","312","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1665","312","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1666","312","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1667","312","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1668","312","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1669","312","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1670","312","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"1671","313","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1672","313","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1673","313","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1674","313","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1675","313","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1676","313","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1677","313","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1678","313","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1679","313","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1680","314","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1681","314","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1682","314","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1683","315","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1684","315","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1685","315","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"1686","315","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"1687","315","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1688","315","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1689","315","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1690","315","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1691","315","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1692","315","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1693","315","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1694","315","rtComments","NNRTI","P236L is a non-polymorphic mutation that has been selected in vitro by DOR and been associated with possible low-level reductions in susceptibility in vitro."
"1695","316","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"1696","316","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"1697","316","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1698","316","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1699","316","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1700","316","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1701","316","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1702","316","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1703","317","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1704","317","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1705","317","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1706","317","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1707","317","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1708","317","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"1709","317","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1710","318","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1711","318","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1712","319","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1713","319","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1714","319","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1715","319","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1716","319","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1717","320","rtComments","Major","G48V is a non-polymorphic mutation selected by SQV and, less often, by IDV and LPV. It confers high-level resistance to SQV, intermediate resistance to ATV, and low-level resistance to NFV, IDV and LPV. G48M is a non-polymorphic mutation selected in viruses with multiple PI-resistance mutations. Its effects appear to be similar to those of G48V. G48A/S/T/Q are rare non-polymorphic mutations selected in viruses with multiple PI-resistance mutations."
"1718","320","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1719","320","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1720","320","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"1721","320","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1722","320","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1723","320","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"1724","320","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1725","320","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1726","320","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1727","320","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1728","320","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1729","320","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1730","320","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1731","320","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"1732","320","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"1733","320","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1734","320","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1735","320","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1736","320","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1737","320","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"1738","321","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1739","322","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1740","322","rtComments","Accessory","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score. V32A is a highly unusual mutation at this position."
"1741","322","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1742","322","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"1743","322","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1744","322","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"1745","322","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1746","322","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1747","322","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"1748","322","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"1749","322","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1750","322","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"1751","322","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219H is an unusual mutation at this position."
"1752","322","rtComments","Other","F227L usually occurs together with V106A. This combination is associated with high-level resistance to NVP and EFV. F227C is a rare non-polymorphic mutation that usually occurs in combination with other NNRTI-resistance mutations. In this context it causes high-level resistance to each of the NNRTIs. F227Y is a highly unusual mutation at this position."
"1753","323","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1754","323","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1755","324","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1756","324","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1757","324","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1758","324","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"1759","324","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"1760","325","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1761","325","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1762","325","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1763","326","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1764","326","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"1765","327","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1766","327","rtComments","Other","V11I is a relatively non-polymorphic accessory mutation selected in patients receiving DRV. It is included in the Tibotec DRV genotypic susceptibility score. V11L is a nonpolymorphic PI-selected mutation associated with reduced DRV and FPV susceptibility when it occurs in combination with other PI-resistance mutations."
"1767","327","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"1768","327","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1769","327","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1770","327","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1771","327","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1772","327","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1773","328","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1774","328","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1775","328","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1776","329","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1777","329","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1778","329","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1779","329","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1780","329","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1781","329","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1782","329","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1783","329","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1784","330","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1785","330","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1786","331","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1787","331","rtComments","Major","In most subtypes, V82M is a 2-base-pair mutation that develops in viruses with multiple other PI-resistance mutations. In subtype G, V82M is a 1-base-pair mutation. V82M reduces susceptibility to IDV, LPV and possibly other PIs."
"1788","331","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1789","331","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1790","331","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1791","331","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"1792","331","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1793","331","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1794","331","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1795","331","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1796","331","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1797","331","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"1798","331","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"1799","331","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"1800","331","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1801","332","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1802","332","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1803","332","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1804","332","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1805","332","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1806","332","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"1807","332","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1808","332","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219D is an unusual mutation at this position."
"1809","332","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1810","332","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"1811","332","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1812","332","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1813","332","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1814","332","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"1815","332","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1816","332","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1817","332","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1818","332","rtComments","NNRTI","G190E is a non-polymorphic mutation that causes intermediate to high-level resistance to each of the NNRTIs. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
"1819","333","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"1820","333","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"1821","333","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1822","333","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1823","333","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1824","333","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1825","333","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1826","333","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1827","333","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1828","334","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1829","335","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1830","335","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1831","335","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"1832","336","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1833","336","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1834","336","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1835","337","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1836","337","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1837","337","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1838","338","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1839","338","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1840","338","rtComments","Other","K238T reduces NVP and EFV susceptibility by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238E is a highly unusual mutation at this position."
"1841","339","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1842","339","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1843","339","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1844","339","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"1845","339","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"1846","339","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"1847","339","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1848","339","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1849","339","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"1850","339","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"1851","339","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1852","339","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1853","339","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"1854","339","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1855","339","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1856","339","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1857","339","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"1858","339","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"1859","339","rtComments","NNRTI","Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
"1860","339","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"1861","340","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1862","340","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"1863","340","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1864","340","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"1865","340","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1866","340","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1867","340","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"1868","340","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"1869","340","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1870","340","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1871","340","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1872","340","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1873","340","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1874","340","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"1875","340","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1876","340","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1877","340","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"1878","340","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1879","341","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1880","341","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"1881","341","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1882","342","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1883","342","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1884","342","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"1885","342","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"1886","342","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"1887","342","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1888","342","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1889","343","rtComments","Major","V82F is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs."
"1890","343","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"1891","343","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1892","343","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1893","343","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1894","343","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1895","343","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1896","343","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"1897","343","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1898","343","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1899","343","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1900","343","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1901","343","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1902","343","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1903","344","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10M is a highly unusual mutation at this position."
"1904","344","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1905","344","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1906","344","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1907","345","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1908","345","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"1909","345","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"1910","345","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1911","345","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"1912","345","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1913","345","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1914","345","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1915","345","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"1916","345","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1917","345","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1918","345","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1919","345","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"1920","345","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1921","346","rtComments","Accessory","G48V is a non-polymorphic mutation selected by SQV and, less often, by IDV and LPV. It confers high-level resistance to SQV, intermediate-level resistance to ATV, and low-level resistance to NFV, IDV and LPV. G48M is a non-polymorphic mutation selected in viruses with multiple PI-resistance mutations. Its effects appear to be similar to those of G48V. G48A/S/T/Q are rare non-polymorphic mutations selected in viruses with multiple PI-resistance mutations. G48R is a highly unusual mutation at this position."
"1922","346","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1923","346","rtComments","Other","L90M is a non-polymorphic PI-selected mutation which reduces susceptibility to each of the PIs except TPV and DRV. L90W is a highly unusual mutation at this position."
"1924","346","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1925","346","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1926","346","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1927","346","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1928","347","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1929","347","rtComments","Major","V82L is an uncommon non-polymorphic mutation selected by TPV. It reduces TPV susceptibility but its effects on other PIs have not been well studied."
"1930","347","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1931","347","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"1932","347","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1933","347","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1934","347","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1935","347","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1936","347","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1937","347","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"1938","347","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1939","348","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"1940","348","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"1941","348","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"1942","348","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1943","348","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1944","348","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"1945","348","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1946","348","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"1947","348","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1948","348","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1949","348","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"1950","348","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1951","348","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"1952","348","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1953","348","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1954","348","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1955","350","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1956","350","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"1957","350","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1958","350","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"1959","350","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"1960","350","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"1961","350","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"1962","350","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1963","350","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1964","350","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"1965","350","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1966","350","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1967","350","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"1968","350","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1969","350","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"1970","350","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"1971","350","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"1972","351","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1973","351","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"1974","351","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"1975","351","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"1976","351","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1977","351","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1978","351","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1979","351","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"1980","351","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1981","351","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"1982","351","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"1983","352","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"1984","352","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"1985","352","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"1986","352","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"1987","352","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"1988","352","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"1989","352","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"1990","353","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"1991","353","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"1992","353","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"1993","353","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"1994","353","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"1995","353","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"1996","353","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"1997","353","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"1998","353","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"1999","353","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2000","353","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2001","353","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2002","354","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2003","354","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2004","354","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"2005","354","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2006","354","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2007","354","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2008","354","rtComments","Accessory","V82A/T/S/F/C/M are non-polymorphic mutations selected primarily in patients who have received IDV, LPV, or multiple PIs. V82A/S/T are associated with reduced susceptibility to each of the PIs except DRV. V82F is associated with reduced susceptibility to each of the PIs. V82C/M usually occur in viruses with multiple additional PI-resistance mutations and have not been well studied. V82P is a highly unusual mutation at this position."
"2009","354","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"2010","354","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2011","354","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2012","354","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2013","354","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2014","354","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2015","354","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2016","354","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2017","354","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2018","354","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2019","354","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2020","355","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2021","355","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2022","355","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2023","355","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2024","355","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"2025","355","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2026","355","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2027","355","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2028","355","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2029","355","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2030","355","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2031","355","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2032","356","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2033","356","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"2034","356","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2035","356","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2036","356","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2037","356","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2038","356","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2039","356","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"2040","356","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2041","357","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"2042","357","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2043","357","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2044","357","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2045","357","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2046","357","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2047","358","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"2048","358","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2049","358","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2050","358","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"2051","358","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"2052","358","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2053","358","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2054","358","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"2055","358","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2056","359","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2057","359","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2058","359","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2059","360","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"2060","360","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2061","360","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2062","360","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"2063","360","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2064","360","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2065","360","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"2066","360","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2067","360","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"2068","360","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2069","360","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2070","360","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2071","360","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"2072","360","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"2073","360","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2074","360","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2075","360","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2076","360","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2077","360","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"2078","360","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2079","361","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2080","361","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2081","363","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2082","363","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2083","363","rtComments","NRTI","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"2084","363","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"2085","363","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2086","363","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2087","363","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2088","363","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"2089","363","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2090","364","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"2091","364","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2092","364","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2093","364","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2094","364","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2095","365","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2096","365","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2097","365","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2098","365","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2099","365","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2100","365","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2101","365","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2102","365","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2103","365","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2104","366","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2105","366","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2106","367","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2107","367","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2108","367","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2109","367","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2110","367","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2111","367","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2112","367","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2113","367","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2114","368","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2115","368","rtComments","Other","T69D/N/G/S/A/I/E are NRTI-selected mutations. T69P is a highly unusual mutation at this position."
"2116","368","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2117","368","rtComments","Other","F227L usually occurs together with V106A. This combination is associated with high-level resistance to NVP and EFV. F227C is a rare non-polymorphic mutation that usually occurs in combination with other NNRTI-resistance mutations. In this context it causes high-level resistance to each of the NNRTIs. F227S is a highly unusual mutation at this position."
"2118","371","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2119","372","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2120","372","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2121","372","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2122","373","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2123","373","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2124","373","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2125","373","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2126","374","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2127","375","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"2128","375","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2129","376","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2130","376","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2131","376","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2132","376","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2133","376","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"2134","376","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179N is an unusual mutation at this position."
"2135","377","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2136","377","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2137","377","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"2138","377","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219T is an unusual mutation at this position."
"2139","377","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2140","377","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2141","378","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2142","378","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"2143","378","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"2144","378","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"2145","378","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2146","378","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2147","378","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2148","378","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2149","378","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"2150","378","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs. D67I is a highly unusual mutation at this position."
"2151","378","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2152","378","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2153","378","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2154","379","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2155","379","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"2156","379","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2157","379","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2158","379","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2159","379","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2160","379","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2161","379","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2162","379","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2163","379","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2164","380","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"2165","380","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2166","380","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"2167","380","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2168","380","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2169","380","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2170","380","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2171","380","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2172","381","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2173","381","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2174","381","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2175","381","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2176","381","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2177","381","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2178","381","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2179","381","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2180","381","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2181","381","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2182","381","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2183","381","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2184","382","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2185","382","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2186","382","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2187","382","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2188","382","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2189","383","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2190","383","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2191","383","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2192","385","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"2193","385","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2194","385","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"2195","385","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"2196","385","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2197","385","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2198","385","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2199","385","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2200","385","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2201","385","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2202","385","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2203","385","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2204","385","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2205","385","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"2206","388","rtComments","Other","L74M is a polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 5% of patients depending on subtype. L74I occurs in 4% to 40% of patients depending on subtype. L74I is the consensus amino acid for subtype A6 and does not appear to be selected by INSTI therapy. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, L74M and possibly L74I reduce susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
"2207","391","rtComments","Other","S153Y/F are rare non-polymorphic mutations selected in vitro by EVG, DTG, and BIC. S153Y/F reduce RAL, DTG, and possibly BIC susceptibility about 2-fold and EVG susceptibility about 4-fold. S153A is an unusual mutation at this position."
"2208","392","rtComments","Major","Y143C/R/H are non-polymorphic mutations associated with high-level RAL resistance. Alone, they have minimal effects on EVG susceptibility. However, they are associated with intermediate reductions in EVG susceptibility when they occur in combination with one or more accessory INSTI-resistance mutations. Y143 mutations do not reduce susceptibility to DTG, BIC, or CAB."
"2209","392","rtComments","Other","M50I is a polymorphic mutation selected in vitro by DTG and BIC in combination with R263K. It appears to contribute to reduced DTG susceptibility in combination with R263K."
"2210","394","rtComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"2211","396","rtComments","Other","M50I is a polymorphic mutation selected in vitro by DTG and BIC in combination with R263K. It appears to contribute to reduced DTG susceptibility in combination with R263K."
"2212","398","rtComments","Other","M50I is a polymorphic mutation selected in vitro by DTG and BIC in combination with R263K. It appears to contribute to reduced DTG susceptibility in combination with R263K."
"2213","399","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2214","399","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2215","399","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2216","399","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2217","399","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2218","399","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2219","400","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2220","400","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2221","400","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2222","400","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2223","401","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2224","401","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2225","401","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2226","401","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2227","401","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2228","401","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2229","401","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2230","401","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2231","401","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2232","401","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2233","401","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2234","401","rtComments","NNRTI","Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
"2235","403","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2236","403","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2237","403","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2238","404","rtComments","Accessory","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score. V32A is a highly unusual mutation at this position."
"2239","404","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2240","404","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2241","404","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"2242","408","rtComments","Other","L74M is a polymorphic accessory mutations commonly selected by each of the INSTIs. In ARV-naive patients, L74M occurs in 0.5% to 5% of patients depending on subtype. L74I occurs in 4% to 40% of patients depending on subtype. L74I is the consensus amino acid for subtype A6 and does not appear to be selected by INSTI therapy. Alone, L74M/I have minimal, if any, effect on INSTI susceptibility. However, L74M and possibly L74I reduce susceptibility to each of the INSTIs when they occur with major INSTI-resistance mutations. L74F is a rare nonpolymorphic mutation which also contributes reduced susceptibility when it occurs with other INSTI-resistance mutations."
"2243","409","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2244","409","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2245","410","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2246","410","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2247","410","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2248","410","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2249","410","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"2250","411","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2251","412","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2252","412","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2253","413","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2254","413","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2255","413","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2256","413","rtComments","NNRTI","V106A is a non-polymorphic mutation that causes high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR."
"2257","413","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2258","413","rtComments","NNRTI","F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
"2259","413","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2260","415","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2261","415","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"2262","415","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2263","415","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"2264","415","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2265","415","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2266","415","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2267","415","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"2268","415","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"2269","416","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2270","416","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2271","416","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2272","416","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2273","416","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2274","416","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2275","416","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2276","416","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2277","416","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2278","416","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"2279","417","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2280","417","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2281","417","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2282","417","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2283","417","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2284","417","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2285","417","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2286","417","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2287","419","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"2288","419","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2289","419","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2290","419","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2291","419","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2292","419","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2293","420","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"2294","420","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2295","420","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2296","420","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2297","420","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2298","420","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2299","420","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"2300","420","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2301","421","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2302","421","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2303","421","rtComments","Major","N88G/T are extremely rare non-polymorphic PI-selected mutations that reduce susceptibility to NFV and ATV."
"2304","421","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2305","421","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2306","421","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2307","421","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"2308","421","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2309","421","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2310","421","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2311","421","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2312","421","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2313","421","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2314","421","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2315","421","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2316","421","rtComments","NNRTI","V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"2317","421","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2318","422","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2319","422","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"2320","422","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"2321","422","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2322","422","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2323","423","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2324","423","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"2325","423","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2326","423","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2327","423","rtComments","NNRTI","V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"2328","423","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2329","424","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2330","424","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"2331","424","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2332","424","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"2333","424","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"2334","424","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"2335","425","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2336","425","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2337","425","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2338","426","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"2339","426","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2340","426","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2341","426","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"2342","426","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2343","426","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2344","426","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2345","426","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2346","426","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"2347","426","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2348","426","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2349","426","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2350","426","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"2351","426","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2352","426","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2353","426","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2354","426","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"2355","427","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2356","427","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2357","429","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2358","429","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2359","429","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"2360","429","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2361","429","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2362","429","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2363","429","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2364","429","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2365","429","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2366","429","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"2367","430","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"2368","430","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2369","430","rtComments","Major","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score."
"2370","430","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"2371","430","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2372","430","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2373","430","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2374","430","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2375","430","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"2376","430","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2377","430","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2378","430","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2379","430","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"2380","430","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2381","430","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2382","430","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2383","430","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2384","430","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2385","431","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2386","431","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2387","431","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2388","432","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2389","432","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2390","432","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"2391","432","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2392","432","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2393","433","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2394","433","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2395","434","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2396","434","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2397","434","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2398","434","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"2399","434","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2400","434","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2401","434","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2402","434","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2403","435","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2404","435","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"2405","435","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2406","435","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2407","435","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"2408","436","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2409","436","rtComments","Accessory","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to the remaining PIs. I50S is a highly unusual mutation at this position."
"2410","436","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2411","436","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2412","437","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2413","437","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2414","437","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2415","438","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2416","438","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2417","438","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2418","438","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2419","438","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"2420","438","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"2421","438","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"2422","438","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2423","438","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"2424","439","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2425","439","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2426","439","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2427","439","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"2428","439","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2429","439","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"2430","439","rtComments","Accessory","T74P is a non-polymorphic PI-selected accessory mutation that occurs primarily in viruses from patients who have received multiple PIs. It is associated with reduced susceptibility to each of the PIs. It is included in the Boehringer-Ingelheim TPV and Tibotec DRV genotypic susceptibility scores."
"2431","439","rtComments","NRTI","Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex."
"2432","439","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"2433","439","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2434","439","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2435","439","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2436","439","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2437","439","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2438","439","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2439","440","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2440","440","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2441","440","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2442","440","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"2443","440","rtComments","Accessory","T74P is a non-polymorphic PI-selected accessory mutation that occurs primarily in viruses from patients who have received multiple PIs. It is associated with reduced susceptibility to each of the PIs. It is included in the Boehringer-Ingelheim TPV and Tibotec DRV genotypic susceptibility scores."
"2444","440","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2445","440","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2446","440","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"2447","440","rtComments","Other","I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied."
"2448","440","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2449","440","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2450","440","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2451","440","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2452","440","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2453","440","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"2454","440","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2455","440","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2456","440","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2457","440","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2458","440","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2459","440","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2460","440","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2461","441","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2462","441","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2463","442","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2464","442","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2465","442","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2466","442","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2467","442","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2468","443","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2469","443","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2470","443","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2471","443","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2472","443","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2473","443","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2474","444","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"2475","444","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2476","444","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2477","444","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2478","444","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"2479","444","rtComments","NNRTI","Y188C is a non-polymorphic mutation selected in patients receiving NVP and EFV. It confers high-level resistance to NVP and EFV. It appears to cause little if any reduction in susceptibility to RPV, ETR, or DOR."
"2480","444","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2481","444","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179M is an unusual mutation at this position."
"2482","445","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2483","445","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"2484","445","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"2485","445","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2486","445","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2487","445","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2488","445","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2489","445","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2490","445","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2491","445","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2492","445","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2493","445","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2494","445","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2495","446","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"2496","446","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2497","446","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2498","446","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2499","446","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2500","446","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2501","446","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2502","446","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2503","446","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2504","446","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2505","447","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2506","447","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"2507","447","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"2508","447","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2509","448","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2510","448","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2511","448","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2512","448","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2513","448","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2514","449","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2515","449","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"2516","449","rtComments","Accessory","T74P is a non-polymorphic PI-selected accessory mutation that occurs primarily in viruses from patients who have received multiple PIs. It is associated with reduced susceptibility to each of the PIs. It is included in the Boehringer-Ingelheim TPV and Tibotec DRV genotypic susceptibility scores."
"2517","449","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2518","449","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2519","449","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2520","449","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2521","449","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179N is an unusual mutation at this position."
"2522","451","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"2523","451","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2524","451","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2525","452","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2526","452","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2527","453","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2528","453","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2529","454","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2530","454","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2531","454","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2532","454","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2533","454","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2534","454","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2535","455","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"2536","455","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"2537","455","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2538","455","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2539","455","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2540","455","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2541","455","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"2542","455","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"2543","455","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2544","455","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2545","455","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2546","455","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2547","455","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2548","456","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2549","456","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2550","456","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2551","456","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"2552","456","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2553","457","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2554","457","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2555","457","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"2556","457","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2557","457","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"2558","457","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2559","457","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2560","457","rtComments","Other","I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied."
"2561","457","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2562","457","rtComments","NRTI","Amino acid insertions between codons 67 and 70 are by convention assigned to codon 69. Together with TAMs, they are associated with high-level resistance to AZT, d4T, ddI, ABC and TDF and intermediate to 3TC and FTC."
"2563","457","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"2564","457","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2565","457","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2566","457","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2567","457","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2568","458","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2569","458","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2570","459","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2571","459","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2572","459","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2573","460","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2574","460","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"2575","460","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"2576","460","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2577","460","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2578","460","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"2579","460","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2580","460","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2581","460","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"2582","460","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2583","460","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2584","460","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2585","460","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2586","460","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2587","460","rtComments","NRTI","K219W is an uncommon NRTI-selected mutation."
"2588","460","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2589","460","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"2590","460","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"2591","461","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2592","461","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2593","461","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2594","462","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2595","462","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2596","462","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2597","462","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2598","462","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"2599","462","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2600","462","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2601","462","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179Q is an unusual mutation at this position."
"2602","462","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2603","463","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"2604","463","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2605","463","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2606","463","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2607","463","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2608","463","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2609","463","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179A is an unusual mutation at this position."
"2610","463","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2611","463","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2612","463","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2613","463","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2614","463","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2615","463","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"2616","463","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2617","463","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2618","463","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2619","463","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2620","465","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2621","465","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2622","465","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2623","465","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2624","465","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2625","465","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2626","465","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2627","466","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2628","466","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2629","466","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2630","466","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2631","466","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2632","466","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2633","466","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"2634","466","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2635","466","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2636","466","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2637","466","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2638","466","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"2639","467","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2640","467","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2641","467","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2642","467","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2643","468","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2644","468","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"2645","468","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2646","468","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2647","468","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2648","468","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"2649","468","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2650","468","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2651","469","rtComments","Major","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score."
"2652","469","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"2653","469","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"2654","469","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2655","469","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2656","469","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2657","469","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2658","469","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2659","469","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2660","470","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2661","470","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"2662","470","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2663","470","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2664","470","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2665","471","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2666","471","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2667","471","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"2668","471","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2669","471","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2670","472","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2671","472","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2672","472","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"2673","472","rtComments","NNRTI","G190E is a non-polymorphic mutation that causes intermediate to high-level resistance to each of the NNRTIs. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
"2674","472","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2675","472","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"2676","472","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2677","473","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2678","473","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2679","473","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2680","473","rtComments","NNRTI","Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
"2681","473","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"2682","474","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2683","474","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2684","474","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2685","474","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2686","474","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2687","474","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"2688","474","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2689","474","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2690","474","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2691","474","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2692","474","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2693","474","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2694","474","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2695","475","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2696","475","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"2697","475","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"2698","475","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"2699","475","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2700","475","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2701","475","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2702","475","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2703","475","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"2704","475","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2705","476","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"2706","476","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2707","476","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"2708","476","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2709","476","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2710","476","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2711","476","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2712","476","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2713","476","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2714","476","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2715","476","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2716","476","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2717","476","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2718","477","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2719","477","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2720","477","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2721","477","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2722","477","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2723","477","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2724","477","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2725","477","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2726","477","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2727","477","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2728","477","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2729","477","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"2730","477","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2731","477","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2732","477","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2733","477","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2734","478","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2735","478","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"2736","478","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2737","478","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2738","478","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2739","478","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"2740","478","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2741","478","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2742","478","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2743","479","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2744","479","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"2745","479","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2746","479","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2747","479","rtComments","NNRTI","G190E is a non-polymorphic mutation that causes intermediate to high-level resistance to each of the NNRTIs. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
"2748","480","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2749","480","rtComments","Other","V11I is a relatively non-polymorphic accessory mutation selected in patients receiving DRV. It is included in the Tibotec DRV genotypic susceptibility score. V11L is a nonpolymorphic PI-selected mutation associated with reduced DRV and FPV susceptibility when it occurs in combination with other PI-resistance mutations."
"2750","480","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"2751","480","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2752","480","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2753","480","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2754","480","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2755","481","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2756","481","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2757","481","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2758","481","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2759","481","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2760","481","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"2761","481","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T and low-level resistance to ABC, ddI and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations may suggest that the patient may have once had a majority virus population with T215Y/F. T215M is a highly unusual mutation at this position."
"2762","481","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2763","481","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2764","481","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"2765","481","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2766","481","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2767","482","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2768","482","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2769","482","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2770","482","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2771","482","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2772","482","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2773","483","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2774","483","rtComments","Major","V82F is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs."
"2775","483","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2776","483","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"2777","483","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2778","483","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2779","483","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2780","483","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2781","483","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2782","483","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2783","483","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2784","484","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"2785","484","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2786","484","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2787","484","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2788","484","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2789","485","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2790","485","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"2791","485","rtComments","Accessory","T74P is a non-polymorphic PI-selected accessory mutation that occurs primarily in viruses from patients who have received multiple PIs. It is associated with reduced susceptibility to each of the PIs. It is included in the Boehringer-Ingelheim TPV and Tibotec DRV genotypic susceptibility scores."
"2792","485","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2793","485","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2794","485","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2795","485","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2796","485","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2797","485","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2798","486","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2799","486","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2800","487","rtComments","Major","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. It is included in the Tibotec DRV genotypic susceptibility score."
"2801","487","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2802","487","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2803","487","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2804","487","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2805","488","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"2806","488","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2807","488","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"2808","488","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2809","488","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"2810","488","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"2811","488","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2812","488","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2813","488","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"2814","488","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2815","488","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2816","488","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2817","488","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2818","488","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2819","488","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2820","488","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2821","488","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2822","488","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2823","488","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2824","489","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2825","489","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2826","489","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"2827","489","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2828","489","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2829","489","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"2830","489","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2831","489","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"2832","489","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2833","489","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2834","489","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2835","489","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2836","489","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2837","489","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"2838","489","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"2839","489","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2840","489","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2841","489","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2842","489","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2843","489","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2844","490","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"2845","490","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2846","490","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2847","490","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2848","490","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"2849","490","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2850","490","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2851","490","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2852","490","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2853","490","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"2854","490","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2855","490","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"2856","490","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2857","490","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2858","490","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2859","490","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"2860","491","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2861","491","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2862","491","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2863","492","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2864","492","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2865","492","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2866","492","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2867","492","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2868","492","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"2869","492","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"2870","492","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2871","493","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2872","494","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2873","494","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"2874","494","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2875","494","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"2876","494","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"2877","494","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2878","494","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2879","494","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2880","494","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"2881","494","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2882","494","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2883","494","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2884","494","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2885","494","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2886","495","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2887","495","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2888","495","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2889","495","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2890","495","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2891","496","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2892","496","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2893","496","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2894","497","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2895","497","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"2896","497","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"2897","497","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"2898","497","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2899","497","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"2900","497","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2901","497","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2902","497","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2903","497","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"2904","497","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2905","497","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2906","497","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2907","497","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2908","497","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2909","497","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"2910","498","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2911","498","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2912","498","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2913","498","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2914","498","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"2915","498","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2916","498","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"2917","499","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2918","499","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2919","499","rtComments","NNRTI","Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
"2920","500","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2921","500","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2922","500","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2923","500","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"2924","501","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2925","501","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"2926","501","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"2927","501","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2928","501","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2929","501","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2930","501","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2931","501","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2932","501","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219H is an unusual mutation at this position."
"2933","501","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"2934","501","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"2935","501","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2936","501","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"2937","501","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2938","501","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2939","502","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2940","502","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2941","503","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2942","503","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2943","503","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2944","503","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2945","503","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2946","504","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2947","504","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"2948","504","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"2949","504","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2950","504","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"2951","504","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2952","504","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"2953","504","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"2954","504","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"2955","504","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2956","504","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2957","504","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"2958","504","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"2959","504","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"2960","505","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2961","505","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"2962","505","rtComments","Major","V82F is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs."
"2963","505","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"2964","505","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2965","505","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2966","505","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2967","505","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"2968","505","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"2969","505","rtComments","NRTI","F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M."
"2970","505","rtComments","NRTI","Q151M causes intermediate/high-level resistance to AZT, ddI, d4T and ABC and low-level resistance to TDF, 3TC and FTC. In combination with accessory mutations at positions 62, 75, 77, and 116, Q151M confers high-level resistance to AZT, ddI, d4T and ABC and intermediate resistance to TDF, 3TC and FTC."
"2971","505","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2972","505","rtComments","NNRTI","Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
"2973","506","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"2974","506","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"2975","506","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2976","507","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2977","507","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"2978","507","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"2979","507","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"2980","509","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2981","509","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"2982","509","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2983","509","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"2984","510","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2985","510","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"2986","510","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"2987","510","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2988","511","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2989","511","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"2990","512","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"2991","512","rtComments","Major","I54A/T/S are non-polymorphic PI-selected mutations that occur almost exclusively in viruses with multiple PI-resistance mutations. I54A/T/S are associated with reduced susceptibility to each of the PIs except DRV."
"2992","512","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"2993","512","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2994","512","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"2995","512","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"2996","512","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"2997","512","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"2998","512","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"2999","512","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3000","512","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3001","512","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3002","512","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3003","513","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3004","513","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3005","513","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3006","514","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3007","514","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3008","514","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3009","514","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3010","515","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3011","516","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3012","516","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3013","516","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3014","516","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3015","516","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"3016","516","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3017","516","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"3018","516","rtComments","NNRTI","Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
"3019","516","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3020","517","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3021","518","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3022","518","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3023","518","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"3024","518","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3025","518","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3026","518","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3027","519","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3028","519","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3029","519","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3030","519","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"3031","520","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"3032","520","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3033","520","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3034","520","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3035","520","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3036","520","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3037","520","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3038","520","rtComments","NNRTI","F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
"3039","520","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3040","521","rtComments","Major","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score."
"3041","521","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"3042","521","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3043","521","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"3044","521","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3045","521","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3046","521","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"3047","521","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3048","521","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3049","521","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3050","521","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3051","521","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3052","521","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3053","521","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3054","521","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3055","521","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3056","522","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3057","522","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"3058","522","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3059","522","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3060","522","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3061","522","rtComments","Accessory","G48V is a non-polymorphic mutation selected by SQV and, less often, by IDV and LPV. It confers high-level resistance to SQV, intermediate-level resistance to ATV, and low-level resistance to NFV, IDV and LPV. G48M is a non-polymorphic mutation selected in viruses with multiple PI-resistance mutations. Its effects appear to be similar to those of G48V. G48A/S/T/Q are rare non-polymorphic mutations selected in viruses with multiple PI-resistance mutations. G48R is a highly unusual mutation at this position."
"3062","522","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"3063","522","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3064","522","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3065","522","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3066","522","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3067","522","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"3068","522","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3069","522","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3070","522","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3071","522","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"3072","522","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"3073","527","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3074","528","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3075","528","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3076","528","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"3077","528","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3078","528","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3079","528","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3080","528","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3081","528","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3082","528","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3083","528","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3084","528","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3085","528","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"3086","529","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3087","529","rtComments","Major","I54A/T/S are non-polymorphic PI-selected mutations that occur almost exclusively in viruses with multiple PI-resistance mutations. I54A/T/S are associated with reduced susceptibility to each of the PIs except DRV."
"3088","529","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3089","529","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3090","529","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3091","529","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3092","529","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3093","529","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3094","529","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3095","529","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3096","529","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3097","530","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3098","530","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3099","530","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"3100","530","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3101","530","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"3102","530","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3103","530","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3104","530","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"3105","530","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3106","530","rtComments","NRTI","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"3107","530","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs. D67K is a highly unusual mutation at this position."
"3108","530","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"3109","530","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3110","530","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3111","530","rtComments","NRTI","V75T causes high-level d4T resistance and intermediate ddI resistance."
"3112","530","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3113","530","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3114","530","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3115","530","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3116","530","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3117","531","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3118","531","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3119","532","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3120","533","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3121","533","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"3122","533","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3123","533","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3124","533","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3125","533","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"3126","533","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"3127","533","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"3128","533","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3129","533","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3130","535","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3131","535","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3132","535","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3133","536","rtComments","Major","N155H is a non-polymorphic mutation selected in patients receiving RAL, EVG, and rarely DTG. It is associated with high-level reductions in RAL and EVG susceptibility. It causes low-level reductions in DTG susceptibility."
"3134","536","rtComments","Other","V151I is an accessory INSTI selected mutation that occurs in 1% to 5% of viruses from ARV-naive patients depending on subtype. Alone, it appears to have little or no effect on INSTI susceptibility."
"3135","538","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3136","538","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3137","538","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3138","538","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3139","538","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3140","538","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3141","538","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3142","538","rtComments","NNRTI","V106A is a non-polymorphic mutation that causes high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR."
"3143","538","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3144","539","rtComments","Major","T66A is a non-polymorphic mutation selected in patients receiving EVG and RAL, usually in combination with other INSTI-resistance mutations. It causes a moderate reduction in EVG susceptibility but does not appear to reduce susceptibility to other INSTIs."
"3145","539","rtComments","Major","G118R is a rare non-polymorphic mutation selected in patients receiving RAL and DTG and in vitro by DTG. Depending on the mutational context it causes 3 to 30-fold reduced susceptibility to each of the INSTIs."
"3146","539","rtComments","Major","E138K/A are non-polymorphic mutations selected in patients receiving RAL, EVG, and DTG. They usually occur in combination with Q148 mutations. Alone they do not reduce INSTI susceptibility. However, when they occur in combination with Q148 mutations, they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG and BIC susceptibility. E138T is an uncommon nonpolymorphic INSTI-selected mutation that appears to have an effect similar to E138K/A."
"3147","541","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3148","541","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3149","541","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3150","541","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3151","541","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3152","542","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3153","542","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3154","542","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3155","542","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3156","542","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3157","542","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3158","542","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"3159","543","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3160","543","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3161","543","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3162","543","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3163","544","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3164","544","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3165","544","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3166","544","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3167","544","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3168","544","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3169","544","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"3170","544","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3171","544","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"3172","545","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3173","545","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3174","545","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3175","546","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"3176","546","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3177","546","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3178","546","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3179","547","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3180","547","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3181","547","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3182","547","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3183","547","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3184","547","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3185","547","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3186","547","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3187","547","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3188","548","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3189","548","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3190","548","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3191","548","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3192","548","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3193","548","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3194","548","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T and low-level resistance to ABC, ddI and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations may suggest that the patient may have once had a majority virus population with T215Y/F. T215H is a highly unusual mutation at this position."
"3195","548","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3196","548","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3197","549","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3198","549","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3199","549","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3200","549","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3201","549","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3202","549","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3203","549","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3204","549","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3205","549","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3206","549","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3207","549","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3208","549","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3209","550","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3210","550","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"3211","550","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3212","550","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3213","551","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3214","551","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3215","551","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3216","551","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3217","551","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3218","551","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3219","551","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3220","551","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3221","551","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3222","551","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3223","552","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3224","552","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"3225","552","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3226","552","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3227","553","rtComments","Other","M50I is a polymorphic mutation selected in vitro by DTG and BIC in combination with R263K. It appears to contribute to reduced DTG susceptibility in combination with R263K."
"3228","555","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3229","556","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3230","556","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3231","556","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3232","556","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3233","557","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3234","557","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3235","557","rtComments","Accessory","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score. V32A is a highly unusual mutation at this position."
"3236","557","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3237","557","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3238","557","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3239","557","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"3240","557","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3241","557","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3242","557","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3243","557","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3244","557","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3245","559","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"3246","559","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"3247","559","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3248","559","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3249","559","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"3250","559","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3251","559","rtComments","Other","V11I is a relatively non-polymorphic accessory mutation selected in patients receiving DRV. It is included in the Tibotec DRV genotypic susceptibility score. V11L is a nonpolymorphic PI-selected mutation associated with reduced DRV and FPV susceptibility when it occurs in combination with other PI-resistance mutations."
"3252","559","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3253","559","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3254","559","rtComments","Other","E138K is a non-polymorphic RPV-resistance mutation. E138A/Q/G/R are less well studied mutations associated with reduced ETR and RPV susceptibility. E138L is an unusual mutation at this position."
"3255","559","rtComments","NRTI","A62V is an accessory mutation that often occurs in combination with the multi-NRTI resistance mutations K65R or Q151M. A62V is widespread in subtype A viruses in former Soviet Union countries but A62 is otherwise non-polymorphic."
"3256","559","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs. D67A is a highly unusual mutation at this position."
"3257","559","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"3258","559","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3259","559","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3260","559","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3261","559","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3262","559","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3263","559","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3264","559","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3265","559","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3266","559","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3267","559","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"3268","560","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3269","560","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3270","560","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"3271","560","rtComments","NNRTI","K103T is an extremely rare non-polymorphic mutation that appears to cause intermediate/high-level resistance to NVP. It has little if any effect on EFV susceptibility."
"3272","561","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3273","561","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3274","562","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3275","562","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3276","562","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3277","562","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3278","562","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3279","562","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3280","562","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3281","562","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3282","562","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3283","563","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"3284","563","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3285","564","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3286","564","rtComments","Other","M41I is usually an artifact resulting from APOBEC3G-mediated hypermutation."
"3287","564","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3288","564","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3289","564","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3290","564","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3291","564","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3292","564","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3293","564","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3294","564","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3295","565","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3296","565","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3297","565","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3298","565","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3299","565","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"3300","565","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3301","565","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3302","565","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3303","565","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"3304","565","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3305","565","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3306","565","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3307","565","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3308","565","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"3309","565","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3310","565","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3311","566","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3312","566","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10M is a highly unusual mutation at this position."
"3313","566","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3314","566","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3315","567","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3316","567","rtComments","Other","V11I is a relatively non-polymorphic accessory mutation selected in patients receiving DRV. It is included in the Tibotec DRV genotypic susceptibility score. V11L is a nonpolymorphic PI-selected mutation associated with reduced DRV and FPV susceptibility when it occurs in combination with other PI-resistance mutations."
"3317","567","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3318","568","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3319","568","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3320","569","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3321","569","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3322","569","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3323","569","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3324","569","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3325","569","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"3326","569","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3327","569","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3328","570","rtComments","Accessory","A128T is a relatively nonpolymorphic possible INSTI-selected mutation, which does not appear to reduce INSTI susceptibility"
"3329","571","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3330","571","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3331","571","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3332","571","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3333","571","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3334","571","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3335","571","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"3336","571","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3337","571","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3338","571","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3339","571","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3340","571","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3341","572","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3342","572","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3343","572","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3344","572","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"3345","572","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3346","572","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3347","572","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3348","572","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"3349","572","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3350","572","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3351","572","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3352","572","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3353","572","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3354","572","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3355","573","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3356","573","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3357","573","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3358","573","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3359","573","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3360","573","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3361","573","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3362","574","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3363","574","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3364","574","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3365","576","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3366","576","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"3367","576","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3368","576","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3369","576","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3370","578","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3371","578","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3372","579","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3373","579","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3374","579","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3375","582","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"3376","583","rtComments","Accessory","E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
"3377","584","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3378","604","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"3379","604","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3380","605","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3381","605","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3382","605","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"3383","605","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3384","605","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3385","605","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3386","605","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3387","605","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3388","605","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3389","605","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3390","605","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3391","606","rtComments","Accessory","E157Q is a polymorphic mutation selected in patients receiving RAL and EVG. It appears to have little effect on INSTI susceptibility."
"3392","607","rtComments","Other","M50I is a polymorphic mutation selected in vitro by DTG and BIC in combination with R263K. It appears to contribute to reduced DTG susceptibility in combination with R263K."
"3393","610","rtComments","Major","Q148H/K/R are non-polymorphic mutations selected by RAL, EVG, and rarely DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with near complete resistance to RAL and EVG, high-levels of reduction in CAB susceptibility, and intermediate reductions in DTG and BIC susceptibility. The presence of Q148H/K/R plus two INSTI DRMs is usually associated with high-level reductions in susceptibility to all INSTIs."
"3394","614","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3395","614","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3396","614","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3397","615","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10M is a highly unusual mutation at this position."
"3398","615","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3399","615","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3400","615","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3401","615","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T and low-level resistance to ABC, ddI and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations may suggest that the patient may have once had a majority virus population with T215Y/F. T215P is a highly unusual mutation at this position."
"3402","615","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3403","615","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3404","616","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3405","616","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3406","616","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3407","616","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3408","617","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3409","617","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3410","617","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3411","617","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3412","617","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3413","617","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3414","617","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3415","617","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"3416","617","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3417","617","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3418","617","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3419","617","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"3420","617","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3421","617","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3422","617","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3423","617","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3424","617","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3425","617","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3426","618","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3427","618","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3428","618","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3429","618","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3430","618","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3431","619","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3432","619","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3433","619","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3434","619","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3435","619","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3436","619","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3437","619","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3438","620","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"3439","620","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3440","620","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"3441","620","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3442","620","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3443","621","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3444","621","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"3445","621","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3446","621","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3447","621","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"3448","621","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3449","621","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3450","621","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3451","621","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"3452","621","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3453","621","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"3454","623","rtComments","Other","M50I is a polymorphic mutation selected in vitro by DTG and BIC in combination with R263K. It appears to contribute to reduced DTG susceptibility in combination with R263K."
"3455","624","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3456","624","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3457","624","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3458","625","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3459","625","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3460","626","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3461","626","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3462","626","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3463","626","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3464","626","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3465","626","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3466","626","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3467","626","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3468","626","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3469","626","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3470","626","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3471","626","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3472","627","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3473","627","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3474","627","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3475","627","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3476","627","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3477","627","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3478","628","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3479","628","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"3480","628","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3481","628","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3482","628","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3483","628","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3484","628","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3485","628","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3486","628","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3487","628","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3488","628","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"3489","628","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3490","628","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3491","629","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3492","629","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3493","629","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"3494","629","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3495","629","rtComments","Accessory","K43T is a non-polymorphic PI-selected accessory mutation. K43T is included in the Boehringer-Ingelheim TPV genotypic susceptibility score."
"3496","629","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"3497","629","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3498","629","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3499","629","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"3500","629","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3501","629","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3502","629","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"3503","629","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3504","629","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"3505","629","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3506","629","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3507","629","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3508","629","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3509","629","rtComments","NNRTI","E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR and possibly to DOR."
"3510","630","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"3511","630","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3512","630","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"3513","630","rtComments","Major","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score."
"3514","630","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"3515","630","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3516","630","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3517","630","rtComments","Accessory","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV. I47T is a highly unusual mutation at this position."
"3518","630","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"3519","630","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"3520","630","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3521","630","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3522","630","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3523","630","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3524","630","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3525","630","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3526","630","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3527","630","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3528","631","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3529","631","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"3530","631","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3531","631","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3532","632","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3533","632","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3534","632","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3535","632","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3536","632","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"3537","632","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3538","632","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3539","632","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3540","633","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3541","633","rtComments","NNRTI","K103E/Q are rare mutations that have not been associated with reduced NNRTI susceptibility."
"3542","634","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3543","634","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"3544","634","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3545","635","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3546","635","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3547","635","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3548","635","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3549","635","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"3550","635","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3551","635","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"3552","635","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3553","635","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3554","635","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3555","635","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3556","636","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3557","636","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3558","636","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3559","636","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"3560","636","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3561","636","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3562","636","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3563","636","rtComments","Other","I132M is an extremely rare non-polymorphic mutation associated with uncertain amount of reduced NVP and EFV susceptibility. I132L is a more common, non-polymorphic NNRTI-selected mutation that has not been well studied."
"3564","636","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3565","636","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3566","636","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3567","636","rtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When V75I occurs alone its clinical significance is uncertain."
"3568","636","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3569","636","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3570","636","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3571","636","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3572","636","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3573","637","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3574","637","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3575","637","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3576","637","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3577","637","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3578","637","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3579","637","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3580","637","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"3581","637","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3582","638","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3583","638","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3584","638","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3585","638","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3586","638","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3587","638","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3588","639","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3589","639","rtComments","NNRTI","E138K is a non-polymorphic mutation selected in a high proportion of patients receiving RPV. It reduces RPV susceptibility by 2 to 3-fold and in combination with K101E or the NRTI-resistance mutation M184I, it is sufficient to cause virological failure on a first-line RPV-containing regimen. E138K causes low-level cross-resistance to ETR and possibly to DOR."
"3590","639","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3591","640","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3592","640","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"3593","640","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3594","640","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"3595","640","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3596","640","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"3597","640","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3598","640","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3599","640","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3600","640","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3601","640","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3602","640","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3603","640","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3604","640","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"3605","641","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3606","642","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3607","642","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3608","642","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3609","642","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3610","643","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3611","643","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3612","643","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3613","643","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"3614","643","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3615","643","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3616","643","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3617","643","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3618","643","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3619","643","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3620","643","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3621","643","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3622","643","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"3623","643","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3624","644","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3625","645","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3626","645","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3627","645","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3628","645","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3629","645","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3630","645","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3631","645","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"3632","645","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3633","646","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3634","646","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3635","647","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3636","648","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3637","648","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3638","649","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3639","649","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3640","649","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"3641","649","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3642","650","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3643","650","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3644","650","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3645","650","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3646","651","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3647","651","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3648","651","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3649","651","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3650","652","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3651","652","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3652","652","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"3653","652","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3654","652","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3655","652","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3656","652","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3657","652","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3658","652","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3659","652","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3660","652","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3661","652","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3662","652","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"3663","652","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3664","653","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3665","653","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3666","653","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3667","653","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219G is an unusual mutation at this position."
"3668","653","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3669","653","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3670","653","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3671","654","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3672","654","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3673","655","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3674","655","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3675","655","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3676","655","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3677","655","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3678","655","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3679","656","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3680","656","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"3681","656","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3682","656","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3683","656","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3684","656","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3685","656","rtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"3686","656","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3687","657","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs. D67A is a highly unusual mutation at this position."
"3688","657","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3689","657","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3690","657","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3691","657","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3692","657","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3693","657","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3694","657","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3695","657","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3696","657","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3697","657","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3698","657","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3699","657","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3700","657","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3701","657","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3702","658","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3703","658","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3704","658","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3705","658","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3706","658","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3707","658","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"3708","658","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3709","658","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3710","659","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3711","659","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"3712","659","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3713","659","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3714","661","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3715","661","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3716","661","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3717","661","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"3718","661","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3719","661","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3720","661","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3721","661","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3722","661","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3723","661","rtComments","NNRTI","V106M is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It is selected in vitro and in vivo by DOR and preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"3724","661","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3725","661","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3726","672","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3727","672","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3728","672","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3729","672","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3730","672","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3731","672","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3732","672","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3733","672","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3734","672","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3735","673","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"3736","673","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3737","673","rtComments","Major","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score."
"3738","673","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3739","673","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3740","673","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"3741","673","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3742","673","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"3743","673","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3744","673","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3745","673","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3746","673","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3747","673","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3748","673","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3749","673","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3750","673","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3751","673","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3752","673","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3753","673","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3754","673","rtComments","NNRTI","V106A is a non-polymorphic mutation that causes high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR."
"3755","673","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3756","674","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3757","674","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3758","674","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3759","674","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3760","674","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3761","674","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"3762","674","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3763","674","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"3764","674","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3765","675","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3766","675","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3767","675","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3768","675","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3769","675","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3770","676","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3771","676","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"3772","676","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3773","676","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3774","676","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3775","676","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3776","676","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"3777","677","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3778","678","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3779","678","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3780","678","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3781","679","rtComments","Major","In most subtypes, V82M is a 2-base-pair mutation that develops in viruses with multiple other PI-resistance mutations. In subtype G, V82M is a 1-base-pair mutation. V82M reduces susceptibility to IDV, LPV and possibly other PIs."
"3782","679","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3783","679","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3784","679","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3785","679","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"3786","679","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3787","679","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3788","679","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3789","679","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3790","679","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3791","680","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3792","680","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3793","680","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3794","680","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3795","681","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3796","681","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3797","682","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3798","682","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3799","682","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3800","683","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3801","683","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"3802","683","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3803","683","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3804","685","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3805","685","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3806","686","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3807","686","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3808","686","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3809","687","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"3810","687","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3811","687","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3812","687","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3813","687","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3814","687","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3815","687","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3816","688","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3817","688","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3818","688","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3819","688","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3820","688","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3821","688","rtComments","NNRTI","Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
"3822","689","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3823","689","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3824","689","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"3825","689","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3826","689","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3827","690","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3828","690","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"3829","690","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3830","691","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3831","691","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3832","691","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3833","691","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3834","691","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3835","691","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3836","692","rtComments","Accessory","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to the remaining PIs. I50T is a highly unusual mutation at this position."
"3837","692","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3838","692","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3839","693","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3840","693","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"3841","694","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3842","694","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"3843","694","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3844","694","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3845","695","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3846","695","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3847","695","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3848","696","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3849","696","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3850","696","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"3851","696","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"3852","696","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3853","697","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3854","697","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3855","698","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"3856","698","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3857","699","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3858","699","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3859","699","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3860","699","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3861","699","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3862","699","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3863","700","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3864","700","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3865","700","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"3866","700","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3867","700","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3868","700","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3869","700","rtComments","Other","Insertions between positions 33 and 41 do not appear to be selected by PIs or to reduce PI susceptibility."
"3870","700","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3871","700","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3872","700","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3873","700","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3874","700","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3875","700","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3876","701","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3877","701","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3878","701","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3879","702","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3880","703","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3881","703","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3882","703","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"3883","704","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"3884","704","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"3885","704","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3886","704","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3887","704","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3888","704","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3889","704","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3890","705","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3891","705","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3892","706","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3893","706","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3894","706","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"3895","706","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3896","706","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3897","707","rtComments","Accessory","I50V is a non-polymorphic mutation selected by DRV, LPV and FPV. It causes low-level, intermediate, and high-level resistance to DRV, LPV, and FPV, respectively. I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to the remaining PIs. I50M is a highly unusual mutation at this position."
"3898","707","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3899","707","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3900","707","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3901","707","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3902","708","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3903","708","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3904","708","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3905","708","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"3906","708","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"3907","709","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3908","709","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3909","709","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3910","709","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3911","710","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3912","710","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3913","710","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3914","710","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3915","710","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3916","710","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3917","710","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"3918","710","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3919","710","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3920","710","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"3921","710","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"3922","710","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to d4T and TDF. K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E increases susceptibility to AZT. K70A is an unusual mutation at this position."
"3923","710","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3924","710","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3925","710","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"3926","710","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3927","710","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3928","710","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3929","710","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"3930","710","rtComments","NNRTI","Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV. They each have a weight of 3.0 in the Tibotec ETR genotypic susceptibility score. Their effects on DOR have not been well-characterized."
"3931","710","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3932","711","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3933","712","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3934","712","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3935","713","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3936","713","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3937","713","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"3938","713","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3939","713","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3940","713","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3941","713","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3942","713","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3943","713","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"3944","713","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3945","713","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3946","713","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"3947","714","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3948","714","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3949","715","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3950","715","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"3951","715","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"3952","715","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"3953","715","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"3954","715","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"3955","715","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"3956","715","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3957","715","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3958","715","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3959","715","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"3960","715","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3961","715","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179M is an unusual mutation at this position."
"3962","715","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"3963","715","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"3964","715","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3965","715","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3966","715","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"3967","715","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"3968","715","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3969","715","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"3970","715","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"3971","716","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3972","716","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"3973","716","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3974","716","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"3975","716","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"3976","716","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"3977","716","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3978","717","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3979","717","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3980","717","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"3981","717","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"3982","717","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"3983","717","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"3984","717","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3985","717","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"3986","717","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3987","718","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"3988","718","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"3989","718","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"3990","718","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"3991","718","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"3992","718","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"3993","718","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"3994","718","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"3995","718","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"3996","718","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"3997","719","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"3998","719","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"3999","719","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4000","720","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4001","720","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4002","720","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4003","720","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4004","720","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4005","720","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"4006","720","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4007","759","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4008","759","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4009","760","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4010","760","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4011","761","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4012","761","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4013","762","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4014","762","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"4015","762","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"4016","762","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4017","762","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4018","762","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4019","763","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4020","763","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4021","763","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4022","763","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"4023","763","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"4024","764","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4025","764","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4026","764","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"4027","764","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"4028","764","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4029","765","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4030","765","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"4031","765","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4032","765","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4033","765","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4034","765","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4035","765","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"4036","765","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4037","766","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4038","766","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"4039","766","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"4040","766","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"4041","766","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4042","766","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"4043","766","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4044","766","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"4045","766","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4046","766","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"4047","766","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4048","766","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4049","766","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"4050","766","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4051","767","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"4052","768","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4053","768","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4054","769","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"4055","769","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"4056","769","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4057","769","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4058","770","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"4059","770","rtComments","Major","In most subtypes, V82M is a 2-base-pair mutation that develops in viruses with multiple other PI-resistance mutations. In subtype G, V82M is a 1-base-pair mutation. V82M reduces susceptibility to IDV, LPV and possibly other PIs."
"4060","770","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied."
"4061","770","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"4062","770","rtComments","Other","K20M/V are rare, relatively non-polymorphic PI-selected mutations that have not been well studied."
"4063","770","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"4064","770","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"4065","770","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4066","770","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"4067","770","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4068","770","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4069","770","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"4070","770","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4071","770","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4072","770","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4073","771","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4074","771","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4075","771","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4076","771","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4077","771","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4078","771","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4079","772","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"4080","772","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4081","772","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4082","772","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"4083","773","rtComments","Accessory","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV. M46V is a rare non-polymorphic PI-selected mutation that has not been well studied."
"4084","773","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4085","773","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4086","773","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4087","774","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"4088","774","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4089","774","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4090","774","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4091","775","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4092","775","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"4093","775","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"4094","775","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"4095","775","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4096","775","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"4097","775","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4098","776","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4099","776","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"4100","776","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"4101","776","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4102","777","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4103","777","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4104","777","rtComments","Major","N88G/T are extremely rare non-polymorphic PI-selected mutations that reduce susceptibility to NFV and ATV."
"4105","777","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"4106","777","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"4107","777","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"4108","777","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4109","777","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4110","777","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4111","777","rtComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"4112","777","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4113","777","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4114","777","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4115","777","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"4116","777","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4117","777","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4118","777","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4119","777","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4120","777","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"4121","778","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4122","778","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4123","778","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4124","778","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4125","779","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4126","780","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4127","780","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4128","780","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4129","781","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4130","781","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4131","781","rtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"4132","781","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"4133","782","rtComments","Major","I54M/L are non-polymorphic mutations selected primarily by DRV and FPV. I54M reduces susceptibility to each of the PIs. I54L reduces susceptibility to each of the PIs except TPV. I54M/L are each included in the Tibotec DRV genotypic susceptibility score."
"4134","782","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"4135","782","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"4136","782","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"4137","782","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"4138","782","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4139","782","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"4140","782","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"4141","782","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"4142","782","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4143","782","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4144","782","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4145","782","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4146","782","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4147","782","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"4148","783","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4149","783","rtComments","Major","I50L is a non-polymorphic mutation selected by ATV. It causes high-level resistance to ATV and increases susceptibility to most of the remaining PIs."
"4150","783","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4151","783","rtComments","Major","N88S is a non-polymorphic mutation usually selected by NFV, ATV, or IDV. It causes high-level resistance to NFV and ATV and low-level resistance to IDV and SQV. It increases susceptibility to DRV and FPV."
"4152","783","rtComments","Major","L90M is a non-polymorphic PI-selected mutation that reduces susceptibility to each of the PIs except TPV and DRV."
"4153","783","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"4154","783","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"4155","783","rtComments","Other","A71I/L are non-polymorphic, PI-selected accessory mutations that appear to increase the replication of viruses with other PI-resistance mutations."
"4156","783","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4157","783","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4158","783","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4159","783","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4160","783","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4161","783","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4162","783","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4163","783","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4164","783","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4165","784","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4166","785","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4167","785","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"4168","785","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4169","785","rtComments","NRTI","Amino acid deletions between codons 67 and 70 are rare and usually occur in combination with multiple TAMs, K65R, or the Q151M mutation complex. Deletions at position 67 are more often associated with multiple TAMs. Deletions at positions 69 and 70 are more often associated with K65R or the Q151M mutation complex."
"4170","785","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"4171","785","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4172","785","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4173","785","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4174","785","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4175","785","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4176","786","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4177","786","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4178","787","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"4179","787","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4180","787","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4181","787","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4182","951","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4183","951","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4184","951","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4185","951","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"4186","951","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4187","951","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4188","951","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4189","952","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4190","952","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4191","953","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"4192","953","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"4193","953","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4194","953","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4195","953","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4196","953","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4197","953","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"4198","953","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4199","953","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4200","953","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"4201","954","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10M is a highly unusual mutation at this position."
"4202","954","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"4203","954","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4204","955","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"4205","955","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"4206","955","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"4207","955","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4208","955","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"4209","955","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179N is an unusual mutation at this position."
"4210","955","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4211","955","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4212","955","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"4213","956","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"4214","956","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4215","956","rtComments","Major","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score."
"4216","956","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"4217","956","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"4218","956","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4219","956","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4220","956","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"4221","956","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4222","956","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4223","956","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4224","957","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4225","957","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"4226","957","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4227","957","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4228","957","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"4229","957","rtComments","NNRTI","V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
"4230","958","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"4231","958","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"4232","958","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"4233","958","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4234","958","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4235","958","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"4236","958","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4237","958","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"4238","958","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"4239","958","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4240","958","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4241","959","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"4242","959","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4243","959","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4244","959","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"4245","959","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4246","959","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4247","959","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"4248","959","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4249","959","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"4250","959","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"4251","959","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4252","959","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"4253","961","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4254","961","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4255","961","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"4256","961","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"4257","961","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4258","961","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4259","961","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"4260","961","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"4261","961","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4262","962","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4263","963","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4264","963","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"4265","964","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4266","964","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4267","964","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"4268","964","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"4269","964","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4270","964","rtComments","NNRTI","L234I is a nonpolymorphic mutation selected in persons receiving NVP and EFV. It is also selected in vitro by ETR and DOR. In combination with V106A, it is associated with high-level DOR resistance. Its effect on susceptibility when it occurs alone has not been well characterized."
"4271","964","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"4272","964","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4273","980","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"4274","980","rtComments","NRTI","K65R causes intermediate/high-level resistance to TDF, ddI, ABC and d4T and low/intermediate resistance to 3TC and FTC. K65R increases susceptibility to AZT."
"4275","980","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT. K70Q/N/S/T are rare non-polymorphic NRTI-selected mutations that appear to have resistance profiles similar to K70E/G."
"4276","980","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"4277","980","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4278","980","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"4279","980","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4280","980","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4281","980","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"4282","981","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4283","982","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"4284","982","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"4285","982","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4286","982","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4287","982","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"4288","982","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4289","983","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4290","983","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4291","983","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4292","983","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"4293","983","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4294","983","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4295","985","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4296","985","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4297","985","rtComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"4298","985","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4299","985","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4300","985","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4301","986","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4302","986","rtComments","Major","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score."
"4303","986","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"4304","986","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4305","986","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4306","986","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4307","986","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4308","986","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"4309","986","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"4310","987","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4311","987","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4312","987","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"4313","987","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4314","987","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"4315","987","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4316","987","rtComments","NNRTI","G190S is a non-polymorphic mutation that causes high-level resistance to NVP and EFV. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. Preliminary data suggests it is associated with low/intermediate reductions in DOR susceptibility."
"4317","987","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"4318","988","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4319","988","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4320","989","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4321","989","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4322","990","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4323","990","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4324","990","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4325","990","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4326","991","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4327","992","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4328","992","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"4329","993","rtComments","Major","V32I is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV. It is included in the Tibotec DRV genotypic susceptibility score."
"4330","993","rtComments","Accessory","G73S/T/C/A are non-polymorphic accessory PI-selected mutations. They are associated primarily with reduced susceptibility to ATV, SQV, FPV, IDV, and NFV. G73V/D are rare non-polymorphic PI-selected mutations."
"4331","993","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4332","993","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4333","993","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4334","993","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"4335","993","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4336","993","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4337","993","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4338","993","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4339","993","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4340","993","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"4341","994","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4342","994","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10T is a highly unusual mutation at this position."
"4343","994","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4344","994","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"4345","994","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4346","994","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4347","994","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4348","994","rtComments","NNRTI","L100I is a non-polymorphic mutation that usually occurs in combination with K103N. In this setting it causes high-level resistance to NVP, EFV, and RPV and intermediate resistance to ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Preliminary data suggests it is contributes low to intermediate reductions in DOR susceptibility when it occurs in combination with K103N."
"4349","994","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4350","994","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"4351","995","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4352","995","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"4353","995","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4354","995","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4355","995","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4356","995","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"4357","996","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"4358","996","rtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"4359","996","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4360","996","rtComments","NNRTI","K101P is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and ETR. It has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Its does not appear to reduce DOR susceptibility."
"4361","996","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"4362","996","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4363","996","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"4364","997","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4365","997","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4366","997","rtComments","Other","V179D/E/F/T/L are accessory NNRTI-resistance mutations. V179S is an unusual mutation at this position."
"4367","997","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4368","997","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4369","998","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4370","998","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"4371","998","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4372","998","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"4373","998","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4374","999","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4375","999","rtComments","Other","T69S/A/I/E are relatively polymorphic mutations weakly selected in patients receiving NRTIs. Their effects on NRTI susceptibility have not been well studied."
"4376","999","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4377","999","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4378","999","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4379","999","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4380","999","rtComments","NNRTI","E138R is a rare non-polymorphic accessory mutation selected in vitro by RPV. It is associated with 2 to 3-fold reduced susceptibility to ETR and RPV and possibly to NVP and EFV. Its effect on DOR is not known."
"4381","999","rtComments","NNRTI","V179L is a rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. Its effects on NNRTI susceptibility have not been well studied. It is listed as an RPV-associated resistance mutation in the RPV package-insert."
"4382","1000","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"4383","1000","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4384","1000","rtComments","NRTI","L74V/I cause high-level resistance to ddI and intermediate resistance to ABC."
"4385","1000","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4386","1000","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4387","1000","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"4388","1000","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4389","1001","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4390","1001","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4391","1001","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"4392","1001","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4393","1002","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4394","1002","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4395","1002","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4396","1002","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4397","1002","rtComments","NRTI","K219N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"4398","1002","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4399","1002","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"4400","1002","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4401","1002","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4402","1003","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4403","1003","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4404","1003","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4405","1003","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4406","1003","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs. D67K is a highly unusual mutation at this position."
"4407","1003","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4408","1003","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4409","1003","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"4410","1003","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4411","1003","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4412","1003","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4413","1003","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"4414","1004","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4415","1004","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4416","1004","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4417","1004","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4418","1004","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4419","1004","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4420","1004","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4421","1004","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"4422","1004","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"4423","1004","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4424","1005","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4425","1005","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4426","1005","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4427","1006","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4428","1006","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4429","1006","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4430","1007","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4431","1007","rtComments","NNRTI","V179D is a polymorphic accessory NNRTI-selected mutation. It contributes low-levels reductions in susceptibility to each of the NNRTIs. The combination of V179D and K103R act synergistically to reduce NVP and EFV susceptibility. V179D has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. V179E is a non-polymorphic mutation occasionally selected by NVP and EFV. V179E appears similar to V179D in its effects on NNRTIs. V179D/E do not appear to reduce the virological $Response$ to a first-line EFV-containing regimen."
"4432","1008","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4433","1008","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"4434","1008","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4435","1008","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4436","1009","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4437","1009","rtComments","Major","I84V is a non-polymorphic mutation selected by each of the PIs. It causes high-level resistance to ATV, FPV, IDV, NFV and SQV, intermediate resistance to LPV and TPV, and low-level resistance to DRV."
"4438","1009","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"4439","1009","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"4440","1009","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10P is a highly unusual mutation at this position."
"4441","1009","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4442","1009","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4443","1009","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4444","1009","rtComments","NRTI","T69D is a non-polymorphic mutation that reduces susceptibility to ddI and possibly d4T."
"4445","1009","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4446","1009","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"4447","1009","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4448","1009","rtComments","NRTI","T215F is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4449","1009","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4450","1009","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4451","1010","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4452","1011","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4453","1011","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4454","1011","rtComments","Major","L76V is a non-polymorphic mutation selected by IDV, LPV and DRV. It reduces susceptibility to these PIs and to FPV and NFV. It increases susceptibility to ATV, SQV and TPV. L76V is included in the Tibotec DRV genotypic susceptibility score."
"4455","1011","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4456","1011","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"4457","1011","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4458","1011","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4459","1011","rtComments","Other","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"4460","1011","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4461","1011","rtComments","Other","K238R is a common polymorphism that does not reduce NNRTI susceptibility."
"4462","1011","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4463","1011","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"4464","1011","rtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"4465","1011","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4466","1011","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"4467","1011","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4468","1011","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4469","1011","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"4470","1011","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"4471","1012","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV. L24F/M are uncommon non-polymorphic PI-selected mutations. L24F has a susceptibility profile similar to L24I."
"4472","1012","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4473","1012","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4474","1012","rtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"4475","1012","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4476","1012","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4477","1012","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4478","1012","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4479","1012","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"4480","1012","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4481","1012","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4482","1012","rtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It causes low-level reductions in susceptibility to NVP and DOR. Alone, it does not appear to reduce susceptibility to EFV, ETR, or RPV."
"4483","1012","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4484","1012","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4485","1013","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4486","1013","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"4487","1014","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4488","1014","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4489","1014","rtComments","Other","K219Q/E/N/R/W are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T. K219A is an unusual mutation at this position."
"4490","1015","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4491","1015","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4492","1016","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4493","1016","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4494","1017","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4495","1018","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4496","1019","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4497","1019","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4498","1020","rtComments","Other","L10F/I/V/R/Y are PI-selected accessory mutations. L10P is a highly unusual mutation at this position."
"4499","1020","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4500","1021","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4501","1021","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4502","1021","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4503","1021","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4504","1022","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4505","1022","rtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility in combination with other mutations. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score despite not contributing much to reduced ETR susceptibility. It is commonly selected during DOR treatment in combination with mutations at position 227."
"4506","1022","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"4507","1022","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4508","1036","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4509","1036","rtComments","Other","K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance."
"4510","1036","rtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in patients receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"4511","1036","rtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, K101H further reduces susceptibility to these NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. Its effect on DOR susceptibility is not known."
"4512","1036","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"4513","1037","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4514","1038","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4515","1038","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4516","1038","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4517","1039","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4518","1039","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4519","1040","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4520","1040","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4521","1040","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4522","1040","rtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and d4T and intermediate to high-level resistance to ddI, ABC and TDF."
"4523","1040","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4524","1040","rtComments","NNRTI","K101E is a non-polymorphic primarily accessory mutation that causes intermediate resistance to NVP and RPV, low-level resistance to EFV, and potentially low-level resistance to ETR. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score. It is associated with low-level reductions in DOR susceptibility."
"4525","1040","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4526","1040","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4527","1041","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4528","1041","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4529","1042","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4530","1042","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"4531","1043","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4532","1043","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4533","1043","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4534","1043","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4535","1043","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"4536","1043","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"4537","1044","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4538","1044","rtComments","Major","I47V is a non-polymorphic PI-selected mutation associated with reduced susceptibility to each of the PIs except SQV and ATV. I47V is included in the Tibotec DRV genotypic susceptibility score."
"4539","1044","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4540","1044","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4541","1044","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"4542","1044","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"4543","1044","rtComments","Accessory","F53L is a non-polymorphic accessory PI-selected mutation that reduces susceptibility primarily to ATV, SQV, and NFV."
"4544","1044","rtComments","Accessory","Q58E is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to TPV and possibly other PIs."
"4545","1044","rtComments","Accessory","N83D is a non-polymorphic mutation selected primarily in patients who have received multiple PIs. It is included in the Boehringer-Ingelheim genotypic susceptibility score for TPV."
"4546","1044","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4547","1044","rtComments","Other","T74S is a PI-selected accessory mutation that is polymorphic in most non-B subtypes."
"4548","1044","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4549","1044","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4550","1044","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"4551","1044","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"4552","1044","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4553","1044","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"4554","1058","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"4555","1058","rtComments","NRTI","K70E/G cause low-level resistance to TDF, ABC, DDI and possibly 3TC and FTC. K70E/G increase susceptibility to AZT."
"4556","1058","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4557","1058","rtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in patients receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. It has a weight of 1.5 in the Tibotec ETR genotypic susceptibility score."
"4558","1058","rtComments","NNRTI","G190E is a non-polymorphic mutation that causes intermediate to high-level resistance to each of the NNRTIs. G190Q is a less common non-polymorphic NNRTI-selected mutation that is associated with high-level NVP and EFV resistance. Its effects on RPV, ETR, and DOR susceptibility is not known."
"4559","1058","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"4560","1058","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4561","1058","rtComments","Other","G190R is strongly suspicious for being an artifact of APOBEC-mediated G-to-A hypermutation. It has not been associated with reduced NNRTI susceptibility."
"4562","1059","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4563","1060","rtComments","NRTI","V75M causes intermediate d4T resistance, low-level ddI resistance, and potentially low-level AZT resistance."
"4564","1060","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4565","1060","rtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"4566","1060","rtComments","NNRTI","E138Q/G are non-polymorphic accessory mutations frequently selected in patients receiving ETR and RPV and occasionally in patients receiving NVP and EFV. In most studies, they cause low-level reductions in susceptibility to NVP, RPV, and ETR. Their effects on DOR are not known."
"4567","1060","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4568","1061","rtComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"4569","1061","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4570","1061","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4571","1061","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4572","1061","rtComments","Other","V11I is a relatively non-polymorphic accessory mutation selected in patients receiving DRV. It is included in the Tibotec DRV genotypic susceptibility score. V11L is a nonpolymorphic PI-selected mutation associated with reduced DRV and FPV susceptibility when it occurs in combination with other PI-resistance mutations."
"4573","1061","rtComments","Other","K20I is the consensus amino acid in subtype G and CRF02_AG. In subtypes B and C, K20I is a PI-selected accessory mutation that reduces NFV susceptibility."
"4574","1061","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4575","1061","rtComments","NRTI","E44D is a relatively non-polymorphic accessory mutation and E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs."
"4576","1061","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4577","1061","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4578","1061","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4579","1061","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4580","1061","rtComments","NNRTI","K238T is a non-polymorphic mutation selected in patients receiving NVP and EFV. It usually occurs in combination with K103N. It reduces susceptibility to NVP and EFV by about 5-fold. It may also reduce susceptibility to ETR and RPV. K238N is a non-polymorphic accessory mutation that is also selected by NVP and EFV. It appears to have minimal, if any, effects on NNRTI susceptibility."
"4581","1062","rtComments","Other","E138D is a polymorphism that occurs in 1% to 2% of viruses from INSTI-naive patients. It does not appear to be selected by INSTIs or to reduce INSTI susceptibility."
"4582","1063","rtComments","Major","I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV."
"4583","1063","rtComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It reduces susceptibility to these PIs and contributes cross-resistance to each of the remaining PIs except DRV and TPV."
"4584","1063","rtComments","Accessory","L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced susceptibility to DRV, FPV, IDV, LPV, and NFV."
"4585","1063","rtComments","Accessory","L24I is a non-polymorphic mutation selected by IDV and LPV. It contributes reduced susceptibility to each PI except DRV and TPV."
"4586","1063","rtComments","Accessory","L33F is a relatively non-polymorphic accessory mutation selected by each of the PIs. In combination with other PI-resistance mutations, it is associated with reduced susceptibility to each of the PIs. It is included in the Tibotec DRV genotypic susceptibility score."
"4587","1063","rtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"4588","1063","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4589","1063","rtComments","NRTI","T215Y is a TAM that causes intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF."
"4590","1063","rtComments","NNRTI","Y181C is a non-polymorphic mutation selected in patients receiving NVP, ETR and RPV. It reduces susceptibility to NVP, ETR, RPV, and EFV by >50-fold, 5-fold, 3-fold, and 2-fold, respectively. Although Y181C itself reduces EFV susceptibility by only 2-fold, it has been associated with a reduced $Response$ to an EFV-containing regimen in NNRTI-experienced patients. Y181C has a weight of 2.5 in the Tibotec ETR genotypic susceptibility score. Alone, it does not appear to reduce DOR susceptibility."
"4591","1063","rtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"4592","1063","rtComments","NNRTI","M230I is an extremely rare mutation selected by RPV. Its effects on NNRTI susceptibility have not been well studied. It also often occurs as a result of APOBEC-mediated G-to-A hypermutation resulting in viruses that are likely to be noninfectious."
"4593","1063","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4594","1064","rtComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to each of the PIs except DRV and TPV."
"4595","1064","rtComments","Accessory","L23I is an uncommon non-polymorphic mutation selected primarily by NFV. It causes low-level NFV resistance."
"4596","1064","rtComments","Accessory","L89V is a non-polymorphic PI-selected accessory mutation that contributes reduced susceptibility to FPV, DRV, NFV, and IDV. L89V is included in the Tibotec DRV genotypic susceptibility score. L89T is a rare non-polymorphic PI-selected mutation that has not been well studied."
"4597","1064","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4598","1064","rtComments","Other","A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4599","1064","rtComments","Other","T69N is a relatively non-polymorphic mutation weakly selected in patients receiving NRTIs. In combination with TAMs, it may contribute minimally reduced susceptibility to ddI, d4T, and AZT."
"4600","1064","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4601","1064","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"4602","1064","rtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low-level resistance to ddI and ABC. However, M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT, TDF and d4T and are associated with clinically significant reductions in HIV-1 replication."
"4603","1064","rtComments","NRTI","K219Q/E are accessory TAMS associated with reduced susceptibility to AZT and possibly d4T."
"4604","1064","rtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"4605","1064","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4606","1064","rtComments","NNRTI","V179T is a relatively rare non-polymorphic mutation occasionally selected in patients receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score."
"4607","1064","rtComments","NNRTI","Y188L is a non-polymorphic mutation that causes high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"4608","1065","rtComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"4609","1065","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF."
"4610","1065","rtComments","NRTI","T215Y/F cause intermediate/high-level resistance to AZT and d4T, low-level resistance to ddI, and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once had a majority virus population with T215Y/F."
"4611","1065","rtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility in the absence of other NNRTI-resistance mutations. It also does not appear to reduce DOR susceptibility."
"4612","1066","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4613","1066","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4614","1066","rtComments","NNRTI","K103N is a non-polymorphic mutation that causes high-level reductions in NVP and EFV susceptibility."
"4615","1066","rtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"4616","1067","rtComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and FPV and low/intermediate-resistance to the remaining PIs except ATV and SQV."
"4617","1067","rtComments","Other","K20R is a highly polymorphic PI-selected accessory mutation."
"4618","1067","rtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It has a weight of 1.0 in the Tibotec ETR genotypic susceptibility score but is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"4619","1067","rtComments","Other","V179I is a polymorphic mutation that is frequently selected in patients receiving ETR and RPV. But It has little, if any, direct effect on NNRTI susceptibility."
"4620","1067","rtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT and d4T. When present with other TAMs, it contributes reduced susceptibility to ABC, ddI, and TDF. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that also generally occur in viruses with multiple TAMs."
"4621","1067","rtComments","NRTI","T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations."
"4622","1067","rtComments","NRTI","K70R causes intermediate resistance to AZT and possibly low-level resistance to D4T, DDI, ABC and TDF."
"23502","9630","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23503","9631","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23504","9631","RtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF."
"23505","9631","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23506","9631","RtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal."
"23507","9631","RtComments","NNRTI","Y181I/V are 2-base pair non-polymorphic mutations selected by NVP and ETR. They cause high-level resistance to NVP, ETR, and RPV but not EFV. Their effects on DOR have not been well-characterized."
"23508","9631","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23509","9632","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23510","9632","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23511","9632","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23512","9632","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23513","9632","RtComments","NNRTI","K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility."
"23514","9632","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23515","9632","RtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"23516","9634","RtComments","NRTI","K65R confers intermediate reductions in susceptibility to TDF, ABC, and 3TC/FTC. Other than M184VI, it is the most common DRM emerging in patients receiving TDF/XTC. K65R increases AZT susceptibility. In NRTI-experienced, INSTI-naive patients with K65R, TDF/3TC/DTG is usually highly effective and more effective than AZT/3TC/DTG. However, in patients receiving TDF/3TC/DTG, there is a risk of emergent DTG resistance that does not arise in NRTI-naive patients receiving TDF/3TC/DTG."
"23517","9634","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23518","9634","RtComments","NNRTI","K101E is a non-polymorphic accessory mutation that confers intermediate resistance to NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it occurs with other NNRTI-resistance mutations."
"23519","9634","RtComments","NNRTI","Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
"23520","9634","RtComments","NNRTI","G190S is a non-polymorphic mutation that confers high-level resistance to NVP and EFV. It may also be associated low-levels reductions in DOR susceptibility. It does not appear to be selected by ETR or RPV or to reduce their in vitro susceptibility."
"23521","9634","RtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"23522","9635","RtComments","NNRTI","Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"23523","9635","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23524","9635","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23525","9636","PrComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"23526","9636","PrComments","Major","V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It is associated with reduced susceptibility to LPV and to a lesser extent ATV. It increases DRV susceptibility."
"23527","9636","PrComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"23528","9636","RtComments","NRTI","K65R confers intermediate reductions in susceptibility to TDF, ABC, and 3TC/FTC. Other than M184VI, it is the most common DRM emerging in patients receiving TDF/XTC. K65R increases AZT susceptibility. In NRTI-experienced, INSTI-naive patients with K65R, TDF/3TC/DTG is usually highly effective and more effective than AZT/3TC/DTG. However, in patients receiving TDF/3TC/DTG, there is a risk of emergent DTG resistance that does not arise in NRTI-naive patients receiving TDF/3TC/DTG."
"23529","9636","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23530","9636","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23531","9636","RtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"23532","9636","RtComments","NRTI","F77L usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"23533","9636","RtComments","NRTI","F116Y usually occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is unknown."
"23534","9636","RtComments","NRTI","Q151M causes intermediate/high-level resistance to AZT and ABC, and low-level resistance to TDF, 3TC and FTC. In combination with two or more accessory mutations at positions 62, 75, 77, and 116, it confers high-level resistance to AZT and ABC and intermediate resistance to TDF, 3TC and FTC."
"23535","9636","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23536","9636","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23537","9636","RtComments","NNRTI","Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
"23538","9636","RtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"23539","9636","RtComments","Other","T69D is a nonpolymorphic mutation selected by early NRTIs that does not appear to reduce AZT, ABC, or TDF susceptibility. T69G is a rare non-polymorphic mutation that usually occurs in viruses with a deletion at codon 67 and multiple other NRTI-resistance mutations. T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility. T69LR is a highly unusual mutation at this position."
"23540","9636","RtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"23541","9636","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23542","9637","PrComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"23543","9637","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23544","9637","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23545","9637","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23546","9637","RtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"23547","9637","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23548","9637","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23549","9637","RtComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23550","9638","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23551","9638","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23552","9638","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once been infected with a virus containing T215Y/F."
"23553","9638","RtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"23554","9638","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23555","9638","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23556","9638","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23557","9639","InComments","Major","N155H is a common nonpolymorphic INSTI-resistance mutations. It has been reported in a high proportion of persons developing VF and HIVDR while receiving RAL, EVG, DTG, and CAB. Alone, it reduces RAL and EVG susceptibility about 10 and 30-fold, respectively. It has minimal effect on susceptibility to DTG, BIC, and CAB. However, it likely significantly reduces the genetic barrier to resistance of CAB."
"23558","9639","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23559","9639","InComments","Other","S119R is a polymorphic mutation that is weakly selected by INSTIs usually in combination with several major INSTI-associated DRMs. Alone, it has little, if any effect, on INSTI susceptibility."
"23560","9639","InComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to CAB. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23561","9641","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23562","9642","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23563","9642","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23564","9642","RtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"23565","9642","RtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in persons receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"23566","9642","RtComments","Other","K103R is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold."
"23567","9643","RtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT."
"23568","9643","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23569","9643","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23570","9643","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23571","9643","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23572","9643","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23573","9643","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23574","9643","RtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal."
"23575","9643","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23576","9643","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23577","9643","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23578","9644","InComments","Major","T66A/I are non-polymorphic mutations selected in persons receiving EVG, RAL, and DTG usually in combination with other INSTI-resistance mutations. They cause moderate reductions in EVG susceptibility but do not appear to reduce susceptibility to other INSTIs."
"23579","9644","InComments","Major","G118R is a nonpolymorphic mutation reported in a significant proportion of persons with VF and emergent HIVDR in persons receiving a DTG-containing regimen. It has occasionally been reported in persons receiving other INSTIs. It is associated with greater than 10-fold reduced susceptibility to DTG, 5-10-fold reduced susceptibility to RAL, EVG, and CAB, and about 3 fold reduced susceptibility to BIC. However, the data for BIC are based on the results of a single site-directed mutant."
"23580","9644","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23581","9644","InComments","Accessory","A128T is a relatively nonpolymorphic possible INSTI-selected mutation, which does not appear to reduce INSTI susceptibility."
"23582","9644","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23583","9645","PrComments","Major","M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV."
"23584","9645","PrComments","Major","I47A is a non-polymorphic mutation selected by LPV. It usually occurs in combination with V32I and in this context it confers high-level resistance to LPV and low-level resistance to DRV."
"23585","9645","PrComments","Accessory","K20T is a non-polymorphic accessory PI-selected mutation associated with reduced susceptibility to ATV and LPV."
"23586","9645","PrComments","Accessory","F53L is a nonpolymorphic accessory mutation selected primarily by SQV, IDV, ATV and LPV. In combination with other mutations, It is associated with reduced susceptibility to ATV and possibly LPV. F53Y is an uncommon nonpolymorphic accessory PI-selected mutation that has not been well studied."
"23587","9645","PrComments","Other","L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations."
"23588","9645","PrComments","Other","V82I is a highly polymorphic mutation that is not selected by PIs. It is the consensus amino acid in subtype G viruses."
"23589","9645","PrComments","Other","I85V is a non-polymorphic PI-selected mutation. It has minimal, if any, effects on PI susceptibility."
"23590","9645","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23591","9645","RtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT."
"23592","9645","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23593","9645","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23594","9645","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23595","9646","RtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal."
"23596","9646","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23597","9648","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23598","9648","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23599","9649","InComments","Major","N155H is a common nonpolymorphic INSTI-resistance mutations. It has been reported in a high proportion of persons developing VF and HIVDR while receiving RAL, EVG, DTG, and CAB. Alone, it reduces RAL and EVG susceptibility about 10 and 30-fold, respectively. It has minimal effect on susceptibility to DTG, BIC, and CAB. However, it likely significantly reduces the genetic barrier to resistance of CAB."
"23600","9649","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23601","9649","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23602","9649","InComments","Other","S119R is a polymorphic mutation that is weakly selected by INSTIs usually in combination with several major INSTI-associated DRMs. Alone, it has little, if any effect, on INSTI susceptibility."
"23603","9649","InComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to CAB. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23604","9650","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23605","9650","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23606","9650","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23607","9650","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23608","9650","RtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"23609","9650","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23610","9651","RtComments","NRTI","S68DNR are nonpolymorphic mutations that are selected by TDF. They appear to increase viral fitness and/or further reduce TDF susceptibility when they occur in combination with K65R."
"23611","9651","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23612","9656","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23613","9657","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23614","9657","RtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"23615","9657","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23616","9657","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23617","9658","InComments","Accessory","G163R/K are nonpolymorphic in all subtypes except subtype F. They are accessory resistance mutations as they usually occur in combination with other INSTI-resistance mutations particularly N155H."
"23618","9659","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23619","9661","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23620","9661","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23621","9661","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23622","9661","RtComments","NNRTI","Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"23623","9662","InComments","Major","R263K is a nonpolymorphic mutation selected in vitro by EVG, DTG, BIC, and CAB. It occurs in a high proportion of persons who develop VF and emergent HIVDR while receiving DTG. Alone, it reduces DTG, BIC, and CAB susceptibility about 2-fold and EVG susceptibility about 5-fold. It remains uncertain whether this mutation is a contraindication to continued treatment with DTG or BIC."
"23624","9662","InComments","Accessory","D232N is a common nonpolymorphic accessory mutation selected in persons receiving RAL and EVG. Alone, it has little effect on INSTI susceptibility."
"23625","9662","InComments","Dosage","There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily."
"23626","9663","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23627","9664","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23628","9664","InComments","Other","L74I is a highly polymorphic mutation with a prevalence of 3% to 30% depending on subtype. It is the consensus amino acid in subtype A viruses belonging to the A6 clade. It does not appear to be selected by any of the INSTIs or to reduce their susceptibility."
"23629","9665","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23630","9665","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23631","9667","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23632","9667","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23633","9667","RtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF."
"23634","9667","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23635","9667","RtComments","NNRTI","Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"23636","9668","InComments","Major","G118R is a nonpolymorphic mutation reported in a significant proportion of persons with VF and emergent HIVDR in persons receiving a DTG-containing regimen. It has occasionally been reported in persons receiving other INSTIs. It is associated with greater than 10-fold reduced susceptibility to DTG, 5-10-fold reduced susceptibility to RAL, EVG, and CAB, and about 3 fold reduced susceptibility to BIC. However, the data for BIC are based on the results of a single site-directed mutant."
"23637","9668","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23638","9668","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23639","9669","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23640","9669","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23641","9669","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23642","9669","RtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"23643","9669","RtComments","NNRTI","K101H is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, it contributes reduces susceptibility to these NNRTIs."
"23644","9669","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23645","9669","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23646","9669","RtComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23647","9670","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23648","9670","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23649","9670","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23650","9670","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23651","9670","InComments","Accessory","E157Q is a polymorphic mutation selected in persons receiving RAL, EVG, and possibly the second generation INSTIs. Alone, it appears to have little effect on INSTI susceptibility. It is uncertain whether it contributes to reduced susceptibility in combination with R263K."
"23652","9670","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23653","9670","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23654","9671","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23655","9671","RtComments","NRTI","Y115F causes intermediate resistance to ABC and low-level resistance to TDF."
"23656","9671","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23657","9671","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23658","9671","RtComments","NNRTI","V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/V179D and V106I/V179D act synergistically to reduce NVP and EFV susceptibility."
"23659","9671","RtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"23660","9671","RtComments","NNRTI","K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility."
"23661","9671","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23662","9672","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23663","9672","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23664","9672","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23665","9672","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23666","9673","RtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT."
"23667","9673","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23668","9673","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23669","9673","RtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"23670","9673","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23671","9673","RtComments","Other","K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility. K238Q is a highly unusual mutation at this position."
"23672","9673","RtComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23673","9675","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23674","9677","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23675","9677","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23676","9677","RtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"23677","9677","RtComments","NNRTI","K103S is a non-polymorphic mutation that causes high-level reductions in NVP susceptibility but intermediate reductions in EFV susceptibility. Because K103S is a 2-bp change from the wildtype K and a 1-bp change from K103N, persons with K103S may be likely to have once had K103N."
"23678","9677","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23679","9677","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23680","9677","RtComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23681","9678","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23682","9678","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23683","9678","InComments","Major","S147G is a nonpolymorphic mutation selected in patients receiving RAL, EVG, and DTG. Alone it reduces EVG susceptibility about 5-fold and appears to contribute reduced susceptibility to the remaining INSTIs."
"23684","9678","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23685","9678","InComments","Other","S230N is a polymorphism that is not associated with reduced INSTI susceptibility."
"23686","9678","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23687","9682","InComments","Other","H51Y is an uncommon nonpolymorphic accessory mutation selected in vitro by EVG, DTG, and CAB. Alone, it has minimal if any effect on INSTI susceptibility. H51Q is an unusual mutation at this position."
"23688","9683","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23689","9683","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23690","9683","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23691","9685","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23692","9685","RtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT. D67G/E/S/T/H are non-polymorphic NRTI-selected mutations that generally occur in viruses with multiple TAMs."
"23693","9685","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23694","9685","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23695","9685","RtComments","NRTI","V75I is a relatively non-polymorphic accessory mutation that often occurs in combination with the multi-NRTI resistance mutation Q151M. When it occurs alone, its clinical significance is uncertain."
"23696","9685","RtComments","NRTI","V75T/M/A/S are nonpolymorphic accessory NRTI-selected mutations. They appear to have minimal phenotypic effects on AZT, ABC, and TDF."
"23697","9685","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23698","9685","RtComments","NRTI","L210W is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, L210W and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF."
"23699","9685","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23700","9685","RtComments","NNRTI","V106A is a non-polymorphic mutation that confers high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR."
"23701","9685","RtComments","NNRTI","F227L is a non-polymorphic mutation that usually occurs in combination with V106A. It is selected in vivo and in vitro with both NVP and DOR. In this context it is associated with high-level reductions in NVP and DOR susceptibility and intermediate reductions in EFV susceptibility. F227I/V are extremely rare mutations that have been selected in vitro by DOR."
"23702","9685","RtComments","NNRTI","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs."
"23703","9685","RtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"23704","9685","RtComments","Other","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs. K219W is an uncommon NRTI-selected mutation. K219D is an unusual mutation at this position."
"23705","9686","InComments","Accessory","E157Q is a polymorphic mutation selected in persons receiving RAL, EVG, and possibly the second generation INSTIs. Alone, it appears to have little effect on INSTI susceptibility. It is uncertain whether it contributes to reduced susceptibility in combination with R263K."
"23706","9687","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23707","9689","RtComments","Other","V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. V179F is a non-polymorphic mutation selected in combination with Y181C in persons receiving ETR. V179T is a rare non-polymorphic mutation occasionally selected in persons receiving NNRTIs. V179L is a rare non-polymorphic mutation listed as a RPV-associated resistance mutation by the FDA package insert. V179S is an unusual mutation at this position."
"23708","9690","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23709","9690","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23710","9693","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23711","9693","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23712","9693","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23713","9694","InComments","Major","R263K is a nonpolymorphic mutation selected in vitro by EVG, DTG, BIC, and CAB. It occurs in a high proportion of persons who develop VF and emergent HIVDR while receiving DTG. Alone, it reduces DTG, BIC, and CAB susceptibility about 2-fold and EVG susceptibility about 5-fold. It remains uncertain whether this mutation is a contraindication to continued treatment with DTG or BIC."
"23714","9694","InComments","Dosage","There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily."
"23715","9695","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23716","9695","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23717","9695","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23718","9695","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23719","9695","RtComments","NNRTI","Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
"23720","9695","RtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"23721","9695","RtComments","NNRTI","K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility."
"23722","9695","RtComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23723","9696","InComments","Major","T66A/I are non-polymorphic mutations selected in persons receiving EVG, RAL, and DTG usually in combination with other INSTI-resistance mutations. They cause moderate reductions in EVG susceptibility but do not appear to reduce susceptibility to other INSTIs."
"23724","9696","InComments","Major","G118R is a nonpolymorphic mutation reported in a significant proportion of persons with VF and emergent HIVDR in persons receiving a DTG-containing regimen. It has occasionally been reported in persons receiving other INSTIs. It is associated with greater than 10-fold reduced susceptibility to DTG, 5-10-fold reduced susceptibility to RAL, EVG, and CAB, and about 3 fold reduced susceptibility to BIC. However, the data for BIC are based on the results of a single site-directed mutant."
"23725","9696","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23726","9696","InComments","Accessory","L74M is a common polymorphic INSTI-resistance mutation. It has a prevalence between 1% and 5% among INSTI-nave persons depending on subtype. It appears to be selected by each of the INSTIs. Alone it does not reduce INSTI susceptibility. However, in combination with other INSTI-resistance mutations, it contributes reduced susceptibility to each of the INSTIs."
"23727","9696","InComments","Other","G118R is a nonpolymorphic mutation reported in a significant proportion of persons with VF and emergent HIVDR in persons receiving a DTG-containing regimen. It has occasionally been reported in persons receiving other INSTIs. It is associated with greater than 10-fold reduced susceptibility to DTG, 5-10-fold reduced susceptibility to RAL, EVG, and CAB, and about 3 fold reduced susceptibility to BIC. However, the data for BIC are based on the results of a single site-directed mutant. G118S is an unusual mutation at this position."
"23728","9696","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23729","9697","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23730","9697","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23731","9697","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23732","9697","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23733","9697","RtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal."
"23734","9697","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23735","9697","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23736","9698","InComments","Major","N155H is a common nonpolymorphic INSTI-resistance mutations. It has been reported in a high proportion of persons developing VF and HIVDR while receiving RAL, EVG, DTG, and CAB. Alone, it reduces RAL and EVG susceptibility about 10 and 30-fold, respectively. It has minimal effect on susceptibility to DTG, BIC, and CAB. However, it likely significantly reduces the genetic barrier to resistance of CAB."
"23737","9698","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23738","9698","InComments","Other","S119R is a polymorphic mutation that is weakly selected by INSTIs usually in combination with several major INSTI-associated DRMs. Alone, it has little, if any effect, on INSTI susceptibility."
"23739","9698","InComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to CAB. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23740","9699","RtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"23741","9699","RtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in persons receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"23742","9699","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23743","9701","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23744","9701","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23745","9702","InComments","Other","L74I is a highly polymorphic mutation with a prevalence of 3% to 30% depending on subtype. It is the consensus amino acid in subtype A viruses belonging to the A6 clade. It does not appear to be selected by any of the INSTIs or to reduce their susceptibility."
"23746","9703","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23747","9703","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23748","9705","RtComments","NRTI","K65R confers intermediate reductions in susceptibility to TDF, ABC, and 3TC/FTC. Other than M184VI, it is the most common DRM emerging in patients receiving TDF/XTC. K65R increases AZT susceptibility. In NRTI-experienced, INSTI-naive patients with K65R, TDF/3TC/DTG is usually highly effective and more effective than AZT/3TC/DTG. However, in patients receiving TDF/3TC/DTG, there is a risk of emergent DTG resistance that does not arise in NRTI-naive patients receiving TDF/3TC/DTG."
"23749","9705","RtComments","NRTI","S68DNR are nonpolymorphic mutations that are selected by TDF. They appear to increase viral fitness and/or further reduce TDF susceptibility when they occur in combination with K65R."
"23750","9705","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23751","9705","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once been infected with a virus containing T215Y/F."
"23752","9705","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23753","9705","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23754","9705","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23755","9705","RtComments","NNRTI","V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/V179D and V106I/V179D act synergistically to reduce NVP and EFV susceptibility."
"23756","9705","RtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"23757","9706","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23758","9706","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23759","9706","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23760","9706","InComments","Accessory","G163R/K are nonpolymorphic in all subtypes except subtype F. They are accessory resistance mutations as they usually occur in combination with other INSTI-resistance mutations particularly N155H."
"23761","9706","InComments","Other","S119R is a polymorphic mutation that is weakly selected by INSTIs usually in combination with several major INSTI-associated DRMs. Alone, it has little, if any effect, on INSTI susceptibility."
"23762","9706","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23763","9707","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23764","9709","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23765","9709","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23766","9709","RtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"23767","9709","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23768","9711","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23769","9711","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23770","9711","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23771","9711","RtComments","NNRTI","Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
"23772","9711","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23773","9711","RtComments","Dosage","This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated."
"23774","9712","InComments","Other","L74I is a highly polymorphic mutation with a prevalence of 3% to 30% depending on subtype. It is the consensus amino acid in subtype A viruses belonging to the A6 clade. It does not appear to be selected by any of the INSTIs or to reduce their susceptibility."
"23775","9713","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23776","9715","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23777","9715","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23778","9716","InComments","Major","R263K is a nonpolymorphic mutation selected in vitro by EVG, DTG, BIC, and CAB. It occurs in a high proportion of persons who develop VF and emergent HIVDR while receiving DTG. Alone, it reduces DTG, BIC, and CAB susceptibility about 2-fold and EVG susceptibility about 5-fold. It remains uncertain whether this mutation is a contraindication to continued treatment with DTG or BIC."
"23779","9716","InComments","Dosage","There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily."
"23780","9717","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23781","9717","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23782","9717","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23783","9718","InComments","Major","R263K is a nonpolymorphic mutation selected in vitro by EVG, DTG, BIC, and CAB. It occurs in a high proportion of persons who develop VF and emergent HIVDR while receiving DTG. Alone, it reduces DTG, BIC, and CAB susceptibility about 2-fold and EVG susceptibility about 5-fold. It remains uncertain whether this mutation is a contraindication to continued treatment with DTG or BIC."
"23784","9718","InComments","Dosage","There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily."
"23785","9719","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23786","9719","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23787","9721","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23788","9723","RtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT."
"23789","9723","RtComments","NRTI","T69D is a nonpolymorphic mutation selected by early NRTIs that does not appear to reduce AZT, ABC, or TDF susceptibility."
"23790","9723","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23791","9723","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23792","9723","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23793","9723","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23794","9723","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23795","9723","RtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"23796","9724","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23797","9725","RtComments","NNRTI","V179T is a rare non-polymorphic mutation occasionally selected in persons receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility."
"23798","9727","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23799","9727","RtComments","NNRTI","K101E is a non-polymorphic accessory mutation that confers intermediate resistance to NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it occurs with other NNRTI-resistance mutations."
"23800","9727","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23801","9727","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23802","9729","RtComments","NRTI","K65R confers intermediate reductions in susceptibility to TDF, ABC, and 3TC/FTC. Other than M184VI, it is the most common DRM emerging in patients receiving TDF/XTC. K65R increases AZT susceptibility. In NRTI-experienced, INSTI-naive patients with K65R, TDF/3TC/DTG is usually highly effective and more effective than AZT/3TC/DTG. However, in patients receiving TDF/3TC/DTG, there is a risk of emergent DTG resistance that does not arise in NRTI-naive patients receiving TDF/3TC/DTG."
"23803","9729","RtComments","NRTI","S68DNR are nonpolymorphic mutations that are selected by TDF. They appear to increase viral fitness and/or further reduce TDF susceptibility when they occur in combination with K65R."
"23804","9729","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23805","9729","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23806","9729","RtComments","NNRTI","Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"23807","9729","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23808","9731","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23809","9731","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23810","9732","InComments","Major","R263K is a nonpolymorphic mutation selected in vitro by EVG, DTG, BIC, and CAB. It occurs in a high proportion of persons who develop VF and emergent HIVDR while receiving DTG. Alone, it reduces DTG, BIC, and CAB susceptibility about 2-fold and EVG susceptibility about 5-fold. It remains uncertain whether this mutation is a contraindication to continued treatment with DTG or BIC."
"23811","9732","InComments","Dosage","There is evidence for intermediate DTG resistance. If DTG is used, it should be administered twice daily."
"23812","9733","RtComments","NRTI","S68G is a polymorphic mutation that is often selected in combination with K65R. It partially restores the replication defect associated with K65R."
"23813","9733","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23814","9733","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23815","9733","RtComments","NNRTI","E138A is a common polymorphic accessory mutation weakly selected in persons receiving ETR and RPV. It reduces ETR and RPV susceptibility ~2-fold. Its effect on ETR- and RPV-containing regimens is likely to be minimal."
"23816","9733","RtComments","NNRTI","K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility."
"23817","9733","RtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"23818","9733","RtComments","Other","V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. V179F is a non-polymorphic mutation selected in combination with Y181C in persons receiving ETR. V179T is a rare non-polymorphic mutation occasionally selected in persons receiving NNRTIs. V179L is a rare non-polymorphic mutation listed as a RPV-associated resistance mutation by the FDA package insert. V179N is an unusual mutation at this position."
"23819","9733","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23820","9734","InComments","Accessory","H51Y is an uncommon nonpolymorphic accessory mutation selected in vitro by EVG, DTG, and CAB. Alone, it has minimal if any effect on INSTI susceptibility."
"23821","9734","InComments","Dosage","This virus is predicted to have low-level reduced susceptibility to CAB. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23822","9735","RtComments","NRTI","K65R confers intermediate reductions in susceptibility to TDF, ABC, and 3TC/FTC. Other than M184VI, it is the most common DRM emerging in patients receiving TDF/XTC. K65R increases AZT susceptibility. In NRTI-experienced, INSTI-naive patients with K65R, TDF/3TC/DTG is usually highly effective and more effective than AZT/3TC/DTG. However, in patients receiving TDF/3TC/DTG, there is a risk of emergent DTG resistance that does not arise in NRTI-naive patients receiving TDF/3TC/DTG."
"23823","9735","RtComments","NRTI","S68DNR are nonpolymorphic mutations that are selected by TDF. They appear to increase viral fitness and/or further reduce TDF susceptibility when they occur in combination with K65R."
"23824","9735","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23825","9735","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23826","9735","RtComments","NNRTI","Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"23827","9735","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23828","9737","RtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT."
"23829","9737","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23830","9737","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23831","9737","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once been infected with a virus containing T215Y/F."
"23832","9737","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23833","9737","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23834","9737","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23835","9737","RtComments","NNRTI","V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/V179D and V106I/V179D act synergistically to reduce NVP and EFV susceptibility."
"23836","9737","RtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"23837","9738","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23838","9738","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23839","9738","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23840","9738","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23841","9739","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23842","9741","RtComments","NRTI","D67N is a non-polymorphic TAM associated with low-level resistance to AZT."
"23843","9741","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23844","9741","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23845","9741","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once been infected with a virus containing T215Y/F."
"23846","9741","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23847","9741","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23848","9741","RtComments","NNRTI","V108I is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations."
"23849","9741","RtComments","NNRTI","V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/V179D and V106I/V179D act synergistically to reduce NVP and EFV susceptibility."
"23850","9741","RtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"23851","9742","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23852","9742","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23853","9742","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23854","9742","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23855","9743","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23856","9745","RtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"23857","9746","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23858","9747","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF. T215S/C/D/E/I/V/N/A/L do not reduce NRTI susceptibility but arise from viruses that once contained T215Y/F. The presence of one of these revertant mutations suggests that the patient may have once been infected with a virus containing T215Y/F."
"23859","9747","RtComments","NNRTI","K101E is a non-polymorphic accessory mutation that confers intermediate resistance to NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it occurs with other NNRTI-resistance mutations."
"23860","9747","RtComments","NNRTI","V106L is a non-polymorphic mutation occasionally selected by NNRTIs. It was reported in an isolate from one of the patients with VF on a DOR-containing regimen that had an approximately 15-fold reduced DOR susceptibility. Additional confirmatory phenotypic data are required."
"23861","9747","RtComments","NNRTI","E138R is an extremely rare non-polymorphic accessory mutation selected in vitro by RPV. Its effect on NNRTI susceptibility has not been well studied."
"23862","9747","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23863","9747","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23864","9749","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23865","9749","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23866","9749","RtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"23867","9749","RtComments","NNRTI","Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
"23868","9749","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23869","9749","RtComments","Other","K101Q is a relatively non-polymorphic mutation that is weakly selected in persons receiving NVP and EFV. It is of uncertain phenotypic and clinical significance."
"23870","9749","RtComments","Other","V118I is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs."
"23871","9750","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23872","9750","InComments","Other","L74I is a highly polymorphic mutation with a prevalence of 3% to 30% depending on subtype. It is the consensus amino acid in subtype A viruses belonging to the A6 clade. It does not appear to be selected by any of the INSTIs or to reduce their susceptibility."
"23873","9751","RtComments","NNRTI","A98G is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs."
"23874","9751","RtComments","NNRTI","Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
"23875","9751","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23876","9754","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23877","9754","InComments","Other","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility. G140R is a nonpolymorphic mutation reported in n macaques receiving CAB pre-exposure prophylaxis and in a person receiving simplification therapy with RPV/CAB. It can reduce CAB susceptibility up to 7-fold. G140K is an unusual mutation at this position."
"23878","9754","InComments","Dosage","This virus is predicted to have low-level reduced susceptibility to CAB. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23879","9755","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23880","9756","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23881","9759","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23882","9759","RtComments","NNRTI","K101E is a non-polymorphic accessory mutation that confers intermediate resistance to NVP and RPV and low-level reductions in susceptibility to EFV, ETR, and DOR when it occurs with other NNRTI-resistance mutations."
"23883","9759","RtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility only in combination with other NNRTI-resistance mutations. It is commonly selected in persons receiving DOR in combination with mutations at position 227."
"23884","9759","RtComments","NNRTI","Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. Alone, it does not significantly reduce DOR susceptibility."
"23885","9759","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23886","9759","RtComments","NNRTI","H221Y is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C."
"23887","9759","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23888","9761","RtComments","NNRTI","V106I occurs in 1% to 2% of viruses from untreated persons. It contributes to reduced NNRTI susceptibility only in combination with other NNRTI-resistance mutations. It is commonly selected in persons receiving DOR in combination with mutations at position 227."
"23889","9761","RtComments","NNRTI","K238T/N are uncommon non-polymorphic mutations selected in persons receiving NVP and EFV usually in combination with K103N. Alone, K238T/N appear to have minimal effects on NNRTI susceptibility."
"23890","9761","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23891","9762","InComments","Accessory","E157Q is a polymorphic mutation selected in persons receiving RAL, EVG, and possibly the second generation INSTIs. Alone, it appears to have little effect on INSTI susceptibility. It is uncertain whether it contributes to reduced susceptibility in combination with R263K."
"23892","9764","InComments","Accessory","E157Q is a polymorphic mutation selected in persons receiving RAL, EVG, and possibly the second generation INSTIs. Alone, it appears to have little effect on INSTI susceptibility. It is uncertain whether it contributes to reduced susceptibility in combination with R263K."
"23893","9767","RtComments","NRTI","K70R is a TAM that confers intermediate resistance to AZT and contributes to reduced ABC and TDF susceptibility in combination with other TAMs."
"23894","9767","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23895","9767","RtComments","NRTI","K219E/Q/N/R are accessory TAMS that usually occur in combination with multiple other TAMs."
"23896","9767","RtComments","NNRTI","Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"23897","9767","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23898","9767","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23899","9768","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23900","9768","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23901","9768","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23902","9768","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23903","9768","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23904","9769","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23905","9769","RtComments","NNRTI","P225H is a non-polymorphic EFV-selected mutation that usually occurs in combination with K103N. The combination of P225H and K103N synergistically reduces NVP, EFV and DOR susceptibility."
"23906","9769","RtComments","Other","V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility."
"23907","9770","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
"23908","9771","RtComments","NNRTI","K103N is a non-polymorphic mutation that confers high-level reductions in NVP and EFV susceptibility. It is the most commonly transmitted DRM."
"23909","9771","RtComments","NNRTI","V179T is a rare non-polymorphic mutation occasionally selected in persons receiving NNRTIs. It is associated with minimal, if any, reduction in ETR and RPV susceptibility."
"23910","9771","RtComments","NNRTI","Y188F is a rare non-polymorphic NNRTI-associated mutation that is usually present as part of an electrophoretic mixture. It appears to represent a transitional mutation between Y and L."
"23911","9771","RtComments","NNRTI","Y188L is a non-polymorphic mutation that confers high-level resistance to NVP, EFV, RPV, and DOR, and potentially low-level resistance to ETR."
"23912","9773","RtComments","NRTI","M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddI, ABC and TDF susceptibility."
"23913","9773","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23914","9773","RtComments","NRTI","T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF."
"23915","9773","RtComments","NNRTI","V179D/E are somewhat polymorphic accessory NNRTI-selected mutation. In combination with other NNRTI DRMs, they appear to contribute low-levels of reduced susceptibility to each of the NNRTIs. In particular, the combinations of K103R/V179D and V106I/V179D act synergistically to reduce NVP and EFV susceptibility."
"23916","9773","RtComments","NNRTI","G190A is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR."
"23917","9773","RtComments","Other","V90I is a polymorphic accessory mutation weakly selected by each of the NNRTIs. It is associated with minimal, if any, detectable reduction in NNRTI susceptibility."
"23918","9773","RtComments","Dosage","This virus is predicted to have low-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be relatively contraindicated."
"23919","9774","InComments","Major","E138K/A/T are common nonpolymorphic accessory resistance mutations selected in patients receiving RAL, EVG, CAB, and DTG. Alone they do not reduce INSTI susceptibility. However, they contribute to reduced susceptibility in combination with other mutations particularly those at position 148."
"23920","9774","InComments","Major","G140S/A/C are non-polymorphic mutations that usually occur with Q148 mutations. Alone, they have minimal effects on INSTI susceptibility. However, in combination with Q148 mutations they are associated with high-level resistance to RAL and EVG and intermediate reductions in DTG, BIC, and CAB susceptibility."
"23921","9774","InComments","Major","S147G is a nonpolymorphic mutation selected in patients receiving RAL, EVG, and DTG. Alone it reduces EVG susceptibility about 5-fold and appears to contribute reduced susceptibility to the remaining INSTIs."
"23922","9774","InComments","Major","Q148H/K/R are nonpolymorphic mutations reported in persons receiving RAL, EVG, CAB, and DTG. They nearly always occur in combination with G140A/S or E138K. In this setting they are associated with high-level resistance to RAL, EVG, and CAB, and low-to-intermediate reductions in DTG and BIC susceptibility."
"23923","9774","InComments","Dosage","There is evidence for high-level DTG resistance. If DTG is used, it should be administered twice daily."
"23924","9778","InComments","Accessory","T97A is a polymorphic INSTI-selected mutation that, depending on subtype, occurs in 1% to 5% of viruses from untreated persons. Alone, it has minimal effects on INSTI susceptibility but in combination with other major resistance mutations, it synergistically reduces susceptibility to each of the INSTIs."
"23925","9779","RtComments","NRTI","M184V/I cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC  (3-fold reduced susceptibility). M184V/I are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication."
"23926","9779","RtComments","Other","T69N/S/A/I/E are relatively non-polymorphic mutations weakly selected in persons receiving NRTIs. They may minimally contribute reduced AZT susceptibility."
"23927","9779","RtComments","Other","M230L is an uncommon non-polymorphic mutation selected in persons receiving EFV, NVP, and RPV. It causes intermediate to high-level resistance to each of the NNRTIs. M230I is a rare mutation selected by RPV. M230R is a highly unusual mutation at this position."
"23928","9781","InComments","Other","M50I is a highly polymorphic mutation, which has a prevalence of 3% to 34% in INSTI-nave persons depending on subtype. It has been selected in vitro by DTG and BIC in combination with R263K. It also appears to frequently occur in combination with R263K in patients receiving DTG and BIC. It is uncertain whether it contributes to reduced DTG and CAB susceptibility in combination with R263K."
